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Background: Biomechanical stiffness has been linked to risk of injury and found to be a
measureable characteristic in musculoskeletal disorders. Specific identification of stiffness may
clarify who is most likely to benefit from the trigger point dry needling (TDN). The purpose of
this study is to investigate the reliability and concurrent validity of the MyotonPRO® to the
criterion of shear wave ultrasound elastography for the measurement of biomechanical stiffness in
the infraspinatus, erector spinae, and gastrocnemius of healthy subjects over increasing muscle
contraction. Second purpose is to investigate the biomechanical effects of TDN to latent
myofascial trigger points (MTrPs) in the infraspinatus, erector spinae, or gastrocnemius.
Research Design and Method: The first phase of the study investigated 30 subjects who
completed three levels of muscle contraction in standardized test positions for the infraspinatus,
erector spinae and gastrocnemius. Biomechanical stiffness measures were collected using shear
wave elastography and MyotonPRO®. The second phase of the study investigated 60 new
subjects who were categorized into infraspinatus, erector spinae, or gastrocnemius group based on
an identified latent MTrP. These subjects underwent TDN while monitoring biomechanical
stiffness at baseline, immediately post TDN, and 24 hours later. Analysis: Discriminate ability,
reliability, and correlations were calculated for measured stiffness variable across the three
conditions of contraction in the first phase of the study. Differences between stiffness at baseline
and after TDN were calculated in the second phase of the study. Results: Correlation of the two
measurement methods in the three muscle regions was significant and strongest in the
gastrocnemius. MyotonPRO reliability was excellent, and demonstrated ability to discriminate
between the three levels of muscle contraction. In the second phase, immediate decreased
stiffness was observed in the MTrP following TDN treatment. Significant decreased stiffness was
found in in the erector spinae and gastrocnemius group who also demonstrated a localized twitch
response during TDN. Stiffness returned to near baseline values after 24 hours. Discussion: The
MyotonPRO® stiffness measurement was found to be reliable and discriminate across predefined
muscle contraction intensities. TDN may cause an immediate change in stiffness but this change
was not observed at 24 hours. It is not known whether these effects are present in a symptomatic
population or related to improvements in other clinical outcomes. Future studies are necessary to
determine if a decrease in biomechanical stiffness is an indication of patient improvement in pain
and function.
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Dry Needling of Myofascial Trigger Points: Quantification of the Biomechanical
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CHAPTER 1: INTRODUCTION

BACKGROUND
Structural changes in skeletal muscle can occur with injury and chronic pain
causing abnormal function.1-3 Muscle that undergoes structural change may lead to
altered elasticity and increased risk of injury.4 Research has identified structural and
neurologic changes in the multifidus muscle as a result of chronic pain.1-3
Musculoskeletal injury and disorders are the leading cause of chronic pain in the U.S.5
The chronic pain epidemic in the U.S. costs in excess of $560 billion annually in
healthcare expenses, and lost productivity.5 This epidemic is punctuated by escalating use
of opioids leading to a reported 22.6 million addicted users.6 The costs associated with
chronic pain disability continue to rise.7 The increased cost and decreased quality of
living create a significant societal impact.1-3 Preliminary observations suggest that
muscular injuries have unique stiffness properties that can be characterized with novel
measurement techniques.8-11 Measurement of tissue stiffness affords an opportunity to
progress the understanding of muscle structural deficits that may be related to injury.12,13
Researching improved strategies of musculoskeletal diagnosis and patient matched
intervention is a priority.
Trigger point dry needling (TDN) is becoming more common in clinical practice.
Incorporating research based treatment management strategies in clinic practice is
especially challenging when the evidence is incomplete.14-16 A body of TDN intervention
research is also beginning to take shape. Sound scientific investigations examining the
1

effects of TDN is necessary to understand its utility in patient management. The first
chapter discusses the problem and outlines the foundation to investigate the clinical
effects of biomechanical stiffness following TDN in subjects with myofascial trigger
points (MTrPs).

STATEMENT OF THE PROBLEM
There is a paucity of quality randomized control trials examining the effectiveness
of TDN. A recent systematic review suggests the positive short-term benefit of TDN for
upper quarter myofascial pain.17,18 Conclusions were based on best available evidence
that included 12 randomized control trials (RCT).18,19 Another systematic review found
some evidence, 3 randomized control trials, to suggest tentative support for TDN in
treatment of cervicogenic and tension-type headaches.5,20 The limited number of high
quality control trials investigating the treatment effects of TDN overshadows the
preliminary support for its inclusion in current practice guidelines.18,21,22 Specific
identification of TDN outcomes such as biomechanical stiffness may clarify which
patients are most likely to benefit from the intervention.
New, novel approaches measuring biomechanical properties are currently
available.14-16 Myotonometry and shear wave elastography (SWE) are two measurement
techniques to objectively quantify the biomechanical stiffness of muscle. The objective
measurement of stiffness may serve as a useful outcome tool to understand the role of
TDN intervention in clinical practice. The measurements of biomechanical properties
may also assist future investigations into the mechanism of action of TDN.
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SPECIFIC AIMS
The purpose of this study was to first investigate the reliability and concurrent
validity of the MyotonPro to the criterion of SWE over increasing muscular contractions.
The second specific aim of this study was to investigate the biomechanical effects of
TDN to MTrPs using the MyotonPRO to measure stiffness.

RESEARCH QUESTIONS
The research questions for this investigation were:
1. What is the concurrent validity of the MyotonPro as compared to the criterion
of SWE in the measurement of biomechanical stiffness in the infraspinatus,
erector spinae, and gastrocnemius of healthy subjects over increasing muscle
contraction?
2. What is the instrument test-retest reliability of the MyotonPRO measurement?
3. What is the biomechanical response of a latent MTrP to TDN in the
infraspinatus, erector spinae, or gastrocnemius measured using the
MyotonPro?

RELEVANCE AND SIGNIFICANCE
MTrPs have been reported to contribute to chronic pain.23,24 These taut, painful
fibers were also identified in subjects with cervical pain using sonoelastography.17,18
MTrPs are characterized as hyperalgesic taut fibers of skeletal muscle. These taut fibers
within the muscle create palpable bands or nodules that may cause local pain, and refer
pain elsewhere with soft tissue examination.18,19 Identification by palpation has been
described as a ropiness or nodularity felt by the examiner.19
3

MTrPs are sensitive to direct or indirect compression and are thought to be a
peripheral source of nociception and may contribute to central sensitization of the
nervous system.25 Clinical studies report an abnormal increase in the electric activity
around the motor endplate.26 The increased motor endplate noise or spontaneous
electrical activity (SEA) creates an involuntary muscle contraction that is palpable with
physical exam.27 MTrPs may also give rise to motor dysfunction due to increased tissue
stiffness and restricted range of motion as a result of increased motor unit activity and
muscle fiber contraction. The palpable taut band of a MTrP has been analyzed using
magnetic resonance elastography (MRE).28 The MTrPs is distinguished from the
surrounding tissue by a shear modulus or biomechanical stiffness that was 50% greater
than the surrounding tissue as measured by MRE.28
The presence of MTrPs in muscle may give rise to increased tissue stiffness as a
result of the contracted fibers.28 Stiffness is a biomechanical property that varies in
contractile and non-contractile tissue. Stiffness is the amount of force divided by
deformation or the slope of force vs. deformation.29 Stiffness is dependent on the muscle
structure (length and cross-sectional area), forces applied, and material property of
elasticity.29 Elasticity is an intrinsic biomechanical property of muscle based on the
material composition.30 Elasticity represents the ability of a material to return to its
previous shape following deformation. Material elasticity is independent of the structural
geometry and is established through Young’s modulus.31 Material that is highly resistant
to deformation will also have a higher Young’s modulus. Highly elastic characteristics
translates to increased structural stiffness.29,31,32
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MTrPs may represent a temporary heterogeneous variation of the soft tissue
elasticity. In theory, with MTrPs representing a contracted portion of muscle, the
resultant stiffness measured would be greater than surrounding, non-contracted tissue.
The application of the load perpendicular to the underlying soft tissue constitutes an
assumption that the stiffness measured represents or approximates the deformation
oriented parallel to the fiber direction. The material stiffness of MTrPs may represent a
magnitude that is greater than the variable viscoelastic properties of the local soft tissue
surrounding it. This has been confirmed by magnetic resonance elastography.33The
accurate and precise measurement of this material property may serve to be a useful
biomarker for clinical intervention research. Emerging technologies, such as the
MyotonPro (Myoton AS, Tallinn, Estonia) and ultrasonic SWE (Aixplorer; SuperSonic
Imagine, Aix-en-Provence, France), will enable noninvasive quantification of localized
properties (stiffness, and shear modulus) of resting and active muscle non-invasively.34-36
SWE is a unique non-invasive ultrasound imaging technique that quantifies the
Young’s modulus of soft tissue. The device is available for clinical use and has been used
primarily to measure and diagnose soft tissue tumors.8,18 Despite SWE availability, the
device is not readily accessible for broad clinical research and cost inhibitory (>
$100,000) for use in a physical therapy setting. An alternative measurement tool is
available. The MyotonPro® (Myoton AS, Talinn, Estonia) is a handheld device that
measures superficial tissue stiffness at a clinically affordable cost of entry.14,35,37 The
device measures the material property stiffness using a perpendicular approach causing
compression under a small probe. A criterion reference of SWE will help gauge the
MyotonPro® measurement for future clinical investigations. Biomechanical
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characterization of stiffness using a myotonometer could potentially serve as a valid
concurrent outcome measure to the criterion of SWE. These devices may prove useful to
the diagnosis of MTrPs and quantifying patient response to TDN intervention beyond
subjective reports of pain.
Recently, the quantification of MTrPs biomechanical stiffness and the change
following TDN has been reported using a SWE.18,20,35 Maher et al reported the shear
modulus of a MTrP in the upper trapezius (MTrP) decreased 29.5% immediately
following one TDN application.35 Clinical techniques focused at treating MTrPs include
stretching, massage, acupressure, ultrasound, transcutaneous electrical stimulation, heat,
and TDN. All methods have demonstrated varying levels of utility in small clinical trials,
leaving questions in regards to clinical effectiveness. Two recent systematic reviews have
recommended the use of TDN for immediate pain relief related to MTrPs found in the
upper quarter.18,20 TDN of MTrPs is a neurophysiological intervention technique
performed by physical therapists.38 The intervention is performed using a thin filiform
needle inserted through the skin, underlying soft tissue, and into muscle to stimulate the
MTrPs. The needle insertion may elicit a localized twitch response (LTR). The LTR is a
phenomenon of involuntary contraction of the muscle fibers within and around the MTrP
and is thought to correlate with needling effectiveness.34

SCOPE OF THE INVESTIGATION
Objective in vivo measurement of the biomechanical structural properties of muscle
is a complimentary approach to current clinical assessment. This investigation will use
the MyotonPro® to characterize the biomechanical stiffness of MTrPs pre and post TDN
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intervention. Current available evidence from a recent systematic review suggests TDN
treatment effectiveness compared to placebo in decreasing pain in the short term (<4
weeks).18 This pragmatic and novel approach may identify a clinically relevant biomarker
for trigger point identification and response of clinical TDN intervention. Concurrent
validity and reliability of the MyotonPro® and SWE measurement may assist data
collection in future clinical investigations such as a multi-site randomized control trial.
The proposed investigation required two major resources for completion. The first
major resource was access to SWE. The second major resource needed was two separate
groups of subjects: asymptomatic individuals to examine the concurrent validity of two
measurement devices; and a second group of subjects with MTrPs in the infraspinatus,
erector spinae, and gastrocnemius for TDN intervention. LTC Shane Koppenhaver, PT,
PhD, FAAOMPT, OCS (U.S. Army-Baylor University Doctoral Program in Physical
Therapy) provided access to a SWE device, access to asymptomatic subjects at Fort Sam
Houston, and grant support through the Army Medical Department, Advanced Medical
Technology Initiative. The Department of Physical Therapy at Bradley University
(Peoria, IL) provided access to a MyotonPRO® device.

DEFINITION OF TERMS
Elasticity29 – The property of a material to resist deformation from a force and to quickly
return to its normal shape. The mechanical measure of a material’s elasticity is stiffness.

Stiffness29 – The measure of a material’s elasticity. It is an inherent biomechanical
property of muscle that represents the amount of strain per unit stress. It is the
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deformation of material per unit stress/force. Most commonly quantified as the slope of a
strain-stress curve (Young’s modulus). This material property is dependent on the resting
viscoelastic structure and the contracted active state.

Myofascial Trigger Point19 – Taut fibers of skeletal muscle that are sensitive to direct or
indirect compression and are thought to be a component of musculoskeletal pain. They
create palpable bands or nodules that may cause local pain, and refer pain elsewhere with
soft tissue examination.

Dry Needling34,39 – Treatment for MTrPs, where a needle is inserted into muscle to target
the MTrPs. Needle insertion is typically followed by 2-3 seconds of a small rhythmic
pistoning to elicit a localized twitch response.

Localized twitch response34 – Involuntary muscle contraction of the MTrP and
surrounding fibers following TDN.

Myotonometry – Measurement of biomechanical properties of superficial muscle using
the MyotonPro® device (Myoton AS, Tallinn, Estonia).

Shear wave elastography – Ultrasound imaging measurement of the biomechanical
properties of superficial and deep musculature using the Aixplorer device (SuperSonic
Imagine, Aix-en-Provence, France).

8

Summary
TDN has been found to cause a significant decrease in stiffness of MTrPs in a
small subject sample.35 Current TDN treatment of MTrPs is applied broadly without
regard to who may be more likely to benefit. There is some available evidence to support
TDN but there are too few RCTs to make definitive recommendations.18,20 The
identification of abnormal stiffness and change in that stiffness after TDN may provide
direction for its most appropriate clinical application and future research of an underlying
mechanism. Also, establishing reliability and validity of a more feasible technology in the
MyotonPRO® may facilitate this line of investigation and clinical utilization of such
technology. Objective measurement of the immediate and short-term biomechanical
effects of TDN on MTrPs remains to be elucidated and requires further investigation.
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CHAPTER 2: REVIEW OF THE LITERATURE

INTRODUCTION
Trigger point dry needling is an emerging technique in physical therapy practice
but has roots dating back to the 1940’s and 50’s.40-42 Recent professional visibility is
expanding as evidence from increasing continuing education course offerings. While
trigger point dry needling (TDN) origins date back several decades, research focus is
relatively new with most randomized control trials occurring in the last ten to fifteen
years.43 The purpose of this chapter is to provide a detailed review of research literature
related to myofascial trigger points (MTrPs), the effectiveness of TDN, and measurement
of biomechanical stiffness.

ETIOLOGY OF TRIGGER POINT DRY NEEDLING
TDN is an intervention technique performed by qualified, licensed physical
therapists.38,44 The professions of medicine, dentistry, chiropractic, and acupuncture also
utilize TDN. TDN involves the insertion of a solid filament needle into the muscles of the
body to treat painful musculoskeletal conditions. The “dry” description of needling
practice originates from a confluence of early injection therapy research and later
exposure to acupuncture type needles. The history of TDN in the United States grew
from investigations of injection therapy to treat musculoskeletal pain in the 1940’s and
‘50’s.43 Researchers studied the effects of injecting local anesthetics to treat
musculoskeletal pain in comparison to the absence of substance as a research control.40,41
The absence of injection substance gave rise to the term “dry” needle. Later, the
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technique of TDN transitioned to solid filament needles like those used in acupuncture
instead of the hollow hypodermic needle.
The origins of TDN can be traced to the published account of pain relief caused
by insertion of a needle without injectable substance in 1941.40 Brav and Sigmond
recruited 62 subjects with low back pain (LBP) or sciatica who were then divided into 3
treatment groups. All subjects were treated with needling into the erector spinae
musculature. Twenty-eight subjects received 1% novocaine injection, 17 subjects
received a salt solution, and the final 17 subjects where treated with an empty
hypodermic needle to serve as a control. The novocaine group received the best outcome
with 16 of 28 (57%) subjects reporting temporary or permanent relief of pain. In the
group that received normal saline solution, 9 of 17 (53%) reported some relief of pain.
Finally, the control group was described as a “startling” result with 10 of 17 (59%)
subjects reporting some relief of symptoms. The authors concluded that the needle itself
was the common variable for success in relieving symptoms and not the injectable
substance.
Paulett’s paper, published in 1947 in the Lancet, is recognized as the earliest
mention of the term “dry needling” as an intervention used to treat LBP.41,43 The author
takes a fragmentary approach to reporting 25 subjects diagnosed with “non-organic low
back pain.” Paulett refers to attempts to eliminate pain by injection into the tender lumbar
points. It is difficult to link specific treatment to subject, but the author does mention
TDN tender muscle to successfully treat LBP. The author makes two specific mentions
that relief could be obtained not only from injection of procaine or saline and but even
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intramuscular TDN. The author emphasizes the treatment location as intramuscular and
not cutaneous/subcutaneous thus differentiating TDN from acupuncture.
Early medical science publications established a foundation for the use of TDN
and were followed by growing interest in the application of Chinese acupuncture.43 In
1976, Ghia et al published an investigation considered the first to compare traditional
Chinese acupuncture to TDN.45 Thirty-eight subjects with a wide variety of lower quarter
pain (>6mos) were included in this study. Diagnoses ranged from low back pain,
individuals post surgical spine surgery, recurrent thrombophlebitis, and herpetic
neuralgia. Two outcome instruments were administered at baseline to assess pain
(Global Pain Estimate) and function (North Carolina Pain Clinic Performance Profile).
The Global Pain Estimate requires the subject to rate pain on a scale of 1-100 and the
North Carolina Pain Clinic Performance Profile is a Likert type scale designed to asses
deficits in 8 functional items such as work, sleep, and daily activities. Subjects were
randomly assigned to receive either traditional acupuncture or needling to tender
musculoskeletal areas. Intervention was provided once a day for seven days with a twoday break between the 5th and 6th treatment. The reported results included 9 subjects out
of 38 that experienced greater than 70% improvement in pain and function lasting 2
months or greater. A remaining 7 subjects reported at least 50% improvement lasting at
least 2 weeks. Interestingly, no significant differences were found between the two
needling approaches. In this study, location of needling did not demonstrate a difference
in effectiveness.
The paper by Lewit, published in 1979, reports the clinical experience of TDN in
241 patients.46 The author purposefully chose TDN over the common practice of
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anesthetic injection based on the observation that effect of anesthesia is similar regardless
of type, quantity, and concentration of solution. The author points out that the locally
injected anesthesia lasts only a few hours yet the therapeutic effect lasts much longer.
The identified common denominator is the needle itself.46
The author describes the inclusion of TDN into the subjects’ usual medical care.
The author reported immediate analgesic effects in 271 out of 312 painful structures.46
This response to treatment is loosely correlated to the authors description of “pronounced
and irrepressible pain reaction” when the tender area is needled.46 The author comments
that the overall effectiveness of TDN may be related to the intensity of the pain caused
when the needle is correctly inserted.46 The dosage and frequency of treatment was
unreported. TDN was performed using both hypodermic needles and acupuncture
needles.
Traditional Chinese acupuncture is one of the oldest approaches to health care in
human history. The classic definition of acupuncture procedure is the insertion of needles
into specific points along meridians to interact with the life force or energy call Qi, within
a dynamic system of yin-yang.47 Practitioners of the traditional theory propose that this
will rebalance energy flow in the body.47 This nebulous definition is not consistent with a
scientific foundation and evidence based medicine.48 The identity of traditional
acupuncture is limited to an untestable theory, but modern acupuncture has since been
expanded to include neuroanatomical and physiological rationale.48,49
The convergence of two distinct needling approaches, TDN and acupuncture, to
treating pain could be viewed as a circular argument.50 Professional efforts to claim
jurisdiction over the practice of TDN are ever present, especially between acupuncturists
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and physical therapists.44,51,52 There are similarities between TDN and acupuncture. The
use of solid filament needles in TDN and acupuncture is the clear consistent variable
between the two practices. The primary difference between the two interventions is the
theoretical approach. TDN focuses on the skeletal muscle and associated with trigger
point theory while acupuncture follows a more philosophical concept of Yin and Yang
forces within the body. Modern or medical acupuncture evolved by adopting a scientific
rationale following western medical research.53,54 Western acupuncture splits the
difference between TDN and traditional acupuncture. The consistent overlap in scope of
practice will fuel continued efforts to diverge acupuncture from TDN or vice versa.
However, TDN theory originates from scientific medical research dating back to the
1940’s and 50’s.40-42 The best available evidence for clinical effectiveness of TDN will be
introduced later.

ETIOLOGY OF MYOFASCIAL TRIGGER POINT THEORY
MTrPs are characterized as hyperalgesiac taut fibers of skeletal muscle.19,55 The
taut fibers within the muscle create palpable bands or nodules that may cause local pain,
and refer pain elsewhere with soft tissue examination.19 Early publications of clinical
observation and treatment gave rise to the MTrPs theory and TDN practice.40-42,45,56,57
The following studies serve as a theoretical foundation for this proposed research.
The first published paper to restrict the term “trigger point” to tender points in
muscle was published by Travell, Rinzler, and Herman.56 The authors reported on 58
subjects treated with intramuscular injections of procaine hydrochloride. Subjects were
treated for pain in the upper quarter near the shoulder. Duration of symptoms ranged
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from “less than two months to a year or longer.”56 Treatment was directed at trigger
points found primarily in the upper trapezius and infraspinatus. The authors reported 62%
of the subjects experienced complete relief of symptoms after an average of 3.5
treatments. This early clinical description of care set the stage for future investigations of
MTrPs and TDN intervention.
Travell and Rinzler expanded the concept of MTrPs further in 1952.57 This paper
reported the clinical findings of referred pain caused by trigger points within muscle.
Detailed mapping of the referral area was provided. The authors report the data was
drawn from 1000 patients with pain and identified trigger points. In doing so, Travell and
Rinzler proposed a trigger point generated afferent stimulus resulting in local and referred
pain patterns. These symptoms and referral areas were relieved or abolished following
treatment, which included procaine injection, TDN, sustained trigger point pressure, or
ethyl chloride spraying of overlying skin.

MYOFASCIAL TRIGGER POINT TYPES
MTrPs can be further categorized theoretically as either latent or active by their
clinical presentation.58 Latent MTrPs are described as trigger points that are present
within skeletal muscle that is otherwise pain free.58 The latent MTrP becomes
symptomatic once compressed during manual examination.58 An active MTrP
spontaneously reproduces pain symptoms locally or in a referred pattern.59 Upon
compression of both active and latent MTrPs, local tenderness is reproduced with and
without referred pain. It is hypothesized that a latent MTrP could potentially progress or
transition to an active MTrP due to repetitive overuse, micro or macro-trauma, and
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psychological stress.60 Clinically these active MTrPs may then regress back to latent
MTrPs following the passage of time or direct intervention.60
CLINICAL DIAGNOSIS OF MYOFASCIAL TRIGGER POINTS
The clinical diagnosis of a MTrP relies heavily on the manual skill of palpatory
examination. Distinct accuracy and reliability of trigger point identification in clinical
examination is essential to matched prescription of treatment. Intervention outcomes and
judgment of intervention effectiveness relies on the accurate diagnosis and measurement
of baseline characteristics. Two separate systematic reviews investigated the available
literature to provide a synthesis on the reliability of identifying trigger points through
manual palpation. 61,62
The classical definition of MTrP is a “hyperirritable spot in a taut band of skeletal
muscle that is painful on compression, stretch, overload or contraction of the tissue which
usually responds with a referred pain that is perceived distinct from the spot.”63 This
characterization of MTrPs provides two commonly used variables that can be quantified:
pain and palpable nodule in a taut band of muscle. However, this expert definition is not
well defined and measureable beyond subjective reports of symptoms and reliance on
skilled palpation. A systematic review of the criteria used to diagnose MTrPs in
published research exposed inconsistencies in the MTrP diagnostic process.64 Variability
in criteria used in diagnosing MTrPs highlights a limited consensus between clinicians
and researchers. The six most commonly reported criteria are: tender spot (or nodule) in a
taut band; patient pain recognition on tend spot palpation; predicted pain referral pattern;
local twitch response on muscle palpation; limited range of movement; and tender spot
(without taut band).64
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The diagnostic accuracy and reproducibility of palpation reported in the literature
is difficult to assess. Primarily, investigations of trigger point palpation suffer poor
quality in methodology and varying criteria for diagnosis.61,62 Myburgh et al identified
six studies investigating reliability of trigger point palpation following a search strategy
that excluded studies that failed to report statistics. A quality analysis based on the
Standards for the Reporting of Diagnostic Accuracy guidelines was employed by the
authors to identify three of the remaining six studies that demonstrated medium to high
quality. However, it was noted by the authors that broad methodological problems left
each study vulnerable to bias and error.61 These vulnerabilities included: multiple muscle
site analysis which could result in patient recall bias; sample heterogeneity and unclear
diagnostic criteria; and inconsistent training of examiners and non-standardization of
palpation pressures.61
Lucas et al identified eight studies while using a broader search strategy that
included an additional year of publications (2008 vs. 2007).62 Five of the studies
identified overlapped with the previous systematic review. The authors also used a
checklist to grade the quality based on both the Standards for the Reporting of Diagnostic
Accuracy and the Quality Assessment of Diagnostic Accuracy Studies appraisal tools. A
parallel conclusion on quality assessment was provided. Current publications suffer
significant problems with methodology which threatened the statistical integrity of the
study.62 The authors were most concerned about the research focus on isolated individual
signs versus a composite of the recommended criteria to diagnose a trigger point. Lucas
et al called for future research to include interrater reliability of composite criteria as well
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as reliability of identifying location within the muscle.62 Neither of these important
reliability components was reported as of 2008.
A composite of both systematic reviews concluded the limited number of studies
provided the possibility of moderate evidence for reproducible diagnosis of trigger points
based on individual criteria.61,62 The variables of local tenderness (
and pain reproduction (

, 0.15-1.0)

, 0.29-1.0) achieved acceptable reliability in most of the

investigations but included a wide range.61,62 While subjective reports of tenderness and
pain reproduction achieve acceptable reliability, they are not sufficient to accurately
diagnose a trigger point or rule out other systemic involvement in isolation.
The addition of another objective sign such as a taut band would assist in the
diagnosis of a trigger point and is proposed as an essential criterion. Reported reliability
estimates for a taut band across all studies ranged from

= -0.08 to 1.0.61,62 Both

systematic reviews called for higher quality investigations of a more global, but well
defined assessment that included the taut band and subjective report of tenderness to
palpation or pain reproduction.
The authors Myburgh et al followed their systematic review with a more recent
investigation of interexaminer reliability of trigger point palpation in the upper trapezius
and the influence of clinical experience.65 A global assessment of trigger point diagnosis
was used based on four criteria proposed by Tough et al: a taut band in skeletal muscle;
local tenderness; patient pain recognition; and patient pain referral. 64,65 The existence of
a taut band was considered to be essential for a trigger point diagnosis in this study while
the remaining criteria factored into an overall global assessment.65 Two experienced and
two inexperienced examiners completed examination training that included psychomotor
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skills to standardize pressure and rate of pressure application.65 The experienced
clinicians averaged 5.75 years in chiropractic practice while the inexperienced clinicians
were represented by student chiropractors.65
The sample size of 81 participants consisted of symptomatic neck subjects (n=67)
and asymptomatic subjects (n=14).65 The authors reported trigger point diagnosis
reliability between experienced clinicians was good

= 0.63 (0.37, 0.80) but poor

=

0.22 (-0.01, 0.44) amongst inexperienced clinicians.65 The authors note that pooling the
data into a global assessment may unfairly bias results based on experience.65,66 However,
this approach towards trigger point diagnosis may be more reasonable given the high
variability of criteria signaled out and used in previous studies. Global assessment may
also be more representative of clinical practice.
A more recent study by Barbero et al investigated the intratester reliability of
trigger point identification in the upper trapezius.66 What is interesting is the authors’
focus on the exact physical location of a trigger point and not just the trigger point
existence. A blindfolded examiner identified and located trigger points on the upper
trapezius of 24 subjects using an anatomical landmark system. X and Y coordinates were
established in reference to a line drawn from the acromial angle to the C7 spinous
process. The analysis of intratester reliability demonstrated high correlation for Y
coordinates (ICC(1,1)=0.81) and moderate correlation for x coordinates (ICC(1,1)=0.62).63,66
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INTEGRATED HYPOTHESIS OF MYOFASCIAL TRIGGER POINTS

The integrated hypothesis of MTrPs is the most prominent theory for the etiology
and mechanism of MTrPs.63,67-69 Since its introduction, the original theory has been
updated with advancing scientific support.67-70 While the theory is evolving and based on
a small number of studies, the best available evidence supports the integrated hypothesis.
The integrated hypothesis proposes the origin of MTrPs may occur following
biomechanical overload of the muscle structure.67,70
MTrPs are postulated to occur following biomechanical stress of the muscle
which precipitates the development of a taut band.67 Gerwin et al proposed that
submaximal repetitive muscle contractions, sustained postures, and acute maximal
overload could lead to the evolvement of the MTrP.67,68 Biomechanical overload results
in an energy crisis with persistent small muscle fiber contraction around the motor
endplate. The taut band is theorized to continue due to motor end plate dysfunction
following muscle fiber injury.68,71,72
Normally the central nervous system initiates a muscle contraction by releasing
acetylcholine (ACh) at the motor endplate. ACh is released at the interface between the
alpha motor neuron and the muscle fiber. ACh then binds to post synaptic nicotinic ACh
receptors (AChR) in the muscle cell allowing the movement of sodium & potassium ions
across the muscle cell membrane. This action leads to a slight depolarization of the
muscle cell identified as a miniature end plate potential (MEPP). The summation of
multiple MEPPs activates sarcomere contraction. Remaining ACh is deactivated in the
synaptic cleft by acetylcholinesterase (AChE) following the action potential. The
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integrated hypothesis proposes the biomechanical overload results in dysregulation of this
process.
Biomechanical overload in the muscle fiber following a contraction might
theoretically result in either micro or macro-traumatic stress.67 The deleterious muscle
activity induces a cascade of events that contribute to the development and maintenance
of MTrPs.67 Key events such as localized ischemia, and release of noxious biochemical
substances result in dysfunctional motor endplates.67 Endplate dysfunction characterizes a
vicious cycle of sustained spontaneous electrical activity resulting in depolarization of
post-synaptic membrane of the motor endplate.71-73
The integrated hypothesis proposes the localized environment is the result of
continued depolarization of the motor endplate resulting in an energy crisis and
biochemical imbalance. Continued small fiber muscular contraction increases the local
intramuscular pressure. The change in pressure gradient impedes capillary blood flow and
produces ischemic hypoxia associated with MTrPs. This restriction limits the resupply of
oxygen and ATP creating the proposed energy crisis.
Local oxygen saturation at a MTrP has been reported to be less than 5% of
normal.70,73-75 The lack of oxygen and ATP may allow sarcomeres to stay contracted and
cause altered biochemical concentrations through the acidic pH levels found in active
MTrPs.70,74,75 Elevated biochemical such as calcium gene related peptide (CGRP),
substance P, and bradykinin are found in significantly higher concentrations in local area
of active MTrPs.74-76 A decreased pH and increased CGRP results in a cascade of events.
CGRP facilitates ACh release, magnifies AChR activity, and inhibits AChE activity.
Bradykinin and substance P are inflammatory agents that contribute to muscle
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nociception activation. This biochemical activity further perpetuates MEPPs thus creating
a theoretical mechanism for MTrPs.

BENEFITS VS. RISKS OF TRIGGER POINT DRY NEEDLING
Safety of potential subjects is a primary concern. TDN is minimally invasive and
carries a low risk. However there are potential adverse events associated with the
invasive technique. An adverse event can be defined as “any ill effect, no matter how
small, that is unintended and non-therapeutic.”29,76,77 In this operational definition, mild
side effects are categorically labeled as an adverse event, even if they are harmless and
transitory.
A prospective observational study of adverse events in 229,230 patients that
received acupuncture was reported.29,38,77 This study is arguably the most comprehensive
investigation of adverse events resulting from needling therapy. The results of this study
require taking into account that patients received multiple treatments (n=2.2 million)
while the authors only reported events per patient and not events per treatment.
Prevalence of adverse events per treatment is expectedly much lower given this fact. The
most common adverse events were superficial bleeding/hematoma (6.14%), localized
pain (2.04%), and fatigue (1.15%).4,35,77,78 Uncommon adverse events included local
infection (0.01%), vertigo (0.22%), and nausea (0.15%).37,76,77 The reported adverse
events are concerning but represent minor temporary conditions that are reversible.
Following strict guidelines for clean needle procedures and location of needling
(gastrocnemius) should further reduce the reported minimal risk.
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Brady et al systematically queried patients that received TDN from a physical
therapist to assess risk specifically associated in this setting. A total of 35 therapists
participated and 7629 patient treatments were reported.76,79 1463 (19.18%) mild adverse
events were reported.37,76 Mild events that were the most prevalent included: bleeding;
bruising; pain during and after treatment.14,76,80-85 Less common events included:
drowsiness; feeling faint; headache; and nausea.76,86 The authors suggested that the
reported percent was higher than the Witt study because the methodology was distinctly
different with the patient reporting the side effects.76,87 The higher percentage may then
more accurately represent the patient’s perceived experience versus the therapist. No
severe adverse events occurred but the size of the sample is relatively small which must
be considered. Despite this limitation, the authors report an estimated risk of severe
adverse events to be ≤0.04%.21,76,87-89

CLINICAL EFFECTIVENESS OF TRIGGER POINT DRY NEEDLING
The current body of research investigating TDN effectiveness is small and does
not unequivocally support widespread clinical use. There is emerging but limited
evidence for a positive TDN treatment effect but maybe not more than placebo in some
cases. The tepid conclusions by most SRs are warranted based on the evidence. The few
number of studies are predominately characterized by limitations in methodology and
heterogeneous grouping of musculoskeletal conditions.21,87-90 The heterogeneity of
subject populations increases the risk that a study may have included subjects with nonfavorable prognostic factors for TDN treatment. Reported non-favorable prognostic
factors include chronic pain, high pain intensity, poor quality of sleep, and repetitive
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work.14,36,47,53,87,90 Small sample size RCTs are also common, with many studies
involving less than 50 subjects. The need for adequately powered, randomized placebo
controlled trials is a common conclusion in most evidence reviews. Compounding this
problem is the trend of most SRs to collate RCTs that include both acupuncture and
TDN. As previously mentioned TDN differs from acupuncture in theory and clinical
practice. TDN does not target meridians but rather trigger points within muscle.8-11,47,53,91
Caution was taken when assessing the acupuncture literature while searching for TDN
clinical effectiveness. This literature review will start with reported systematic reviews,
then specifically focus on the regions of the infraspinatus/shoulder, low back/lumbar, and
lower leg/gastrocnemius/foot/ankle.
A systematic review (SR) by Cummings and White reported 23 RCTs to establish
evidence for trigger point needling efficacy.91,92 The randomized control trials (RCT)
included in this SR covered a wide scope of diagnoses ranging from unspecified
myofascial pain to migraines. Sample sizes were generally small and 10 of the 23 RCT’s
were judged to be poor quality.16,91 Five of these RCT’s investigated direct TDN while
the remainder included injected substances along with TDN. The authors reported that 8
of the wet needle trials concluded the effect was independent of the injected
substance.16,91 Any effect of needling intervention is likely because of the needle or
placebo rather than injection of either saline or active drug.9,11,91,93,94 Despite the
heterogeneity and the poor quality of methodologies found, the authors state that needling
appears to be an effective treatment, but it is not supported nor refuted beyond placebo
which requires further research.17,35,41,91,95 The conclusion was based on the collected
results that demonstrated improvement in outcomes following needling intervention
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regardless of dry vs. injected substance. This conclusion echoes previous findings of
Paulett in 1947.41,70,96
An overview of all Cochrane Reviews on needling intervention (acupuncture and
TDN) for the treatment of pain was completed in 2011. Lee and Ernst included 8 reviews
(109 RCTs) related to a wide range of pain syndromes including: osteoarthritis;
migraines; tension type headaches; neck disorders; rheumatoid arthritis; shoulder pain;
low back pain; and lateral elbow pain.67,96 Overall quality of the RCTs was reported as
variable in each review.28,96 Five of the eight reviews reported clinical effectiveness in
reduction of pain for osteoarthritis, migraines, tension type headaches, neck disorders,
and low back pain. The remainder of the Cochrane reviews reported inconclusive
evidence for treatment effectiveness due to low number of published RCTs.18,20,21,35,96
A SR conducted within the framework of the Cochrane Collaboration, by Furlan
et al, focused on low back pain.21,37,79 The scope of the SR was broad including 35 RCT’s
using both acupuncture and TDN techniques. The authors’ description definitively
separates acupuncture from TDN. It is confusing as to why both were combined for this
review. The included RCT’s also covered a broad range of the stage of symptoms from
nonspecific acute, subacute, and chronic low back pain. The authors reported that there
was too few RCT’s to come to any meaningful conclusions due in part to small sample
sizes and poor methodological quality.21,37,79 However, the authors’ describe the
collective data suggests TDN may be a useful addition to treatment for short term pain
relief.21,22,87
Similar, muted, conclusions were drawn in a SR and meta-analysis by Tough and
White. In contrast to the previously mentioned SR’s, the authors limited inclusion to
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needling of MTrPs only and excluded acupuncture treatment approaches. A total of 10
studies were identified for inclusion, while only 6 were included into the meta-analysis.
22,97

The meta-analysis was completed on RCTs that included a sham placebo control. The

authors reported that even though the 6 studies were considered similar in intervention
and outcome tool, the methodological diversity created a statistical heterogeneity
(I2=82.6%) that was higher than the recommended limit according to the Cochrane
Handbook.22,98 The statistical heterogeneity is a consequence of variability in population
groups, number of treatments provided, and small sample sizes.22,98-100 The authors
acknowledge this limitation but suggest that needling combined with usual physical
therapy care such as exercise is more effective at reduction in pain, based on two of the
included studies.18,22,99-101
More recently, Kietrys et al completed a SR and meta-analysis with the focus of
TDN effectiveness in upper quarter myofascial pain. The authors make strong
conclusions that there is now “grade A evidence” to suggest TDN is effective for clinical
pain relief.18,102 Kietrys et al recommend TDN, compared to sham or placebo treatment,
for immediate pain reduction based meta-analysis of four studies with a pooled effect size
of 1.06 (95% CI: 0.05, 2.06).18,102 A strong recommendation may be unsupported as the
confidence interval is very wide and close to zero, suggesting the possibility of small,
meaningless effect size. It is also reported that the pooled results of these four studies had
high statistical heterogeneity (I2=86.3%) and high risk for publication bias.18,103 Based on
meta-analysis of three studies, the authors cautiously recommend TDN, compared to
sham or placebo, for reduction of pain at four weeks.18,103 This conclusion, while
cautious, was determined by an overall effect size of 1.07 (95% CI: -0.21, 2.35).18,104 The
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authors report that the confidence interval crosses zero suggesting the possibility there is
no difference between treatments and high statistical heterogeneity of the three studies
(I2=84.2%).18,34,102
The authors’ conclusions contradict the reported results. The available data for
meta-analysis is limited and in one study other treatment was favored over TDN for
immediate reduction in symptoms.18,30,34,105-107 It is puzzling that the recommendation
favored TDN as “grade A evidence,” considering the limitations in calculated effect size
confidence intervals and high heterogeneity of the comparison studies.18,108-110 Despite
the inconsistent interpretation of the data by the authors, there appears to be some
evidence to support the use of TDN for immediate reduction of pain caused by
MTrPs.88,108-110
Cotchett and colleagues completed a SR review of quasi-experimental
investigations of TDN treatment for plantar fasciitis. The authors identified 3 trials and
all trials reported a reduction in pain following TDN.88,111 The characteristics of the trials
limit the conclusions that can be drawn due to the nature of the quasi-experimental study
design and threat to internal validity. Study sample sizes were very small (n<19),
randomization did not occur, and overall quality was graded <13/27 on the Quality Index
tool.88,112,113 Other limitations include the combined acupuncture and TDN intervention
approach, inconsistency and absence in outcome reporting, and overall statistical
heterogeneity. Despite these limitations, there is a trend towards clinical effectiveness of
TDN but poor quality of the included trials impedes definitive conclusions from being
drawn.
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An overall trend of statistical heterogeneity and poor methodology precludes
strong guidance for the clinical use of TDN. Published SRs tend to use trials with known
sources of bias and poor methodology. There is a lack of robust evidence to suggest the
clinical effectiveness of TDN, if these lower quality studies were excluded from SR.
However, there does appear to be a trend towards clinical benefit in some of the previous
trials as well as more recently reported studies. This proposed investigation will focus on
TDN of latent MTrPs in three regions: infraspinatus; erector spinaes; and gastrocnemius.
The following research investigates these regional areas.
The clinical relevance of latent MTrPs was investigated in a pilot RCT by CalvoLobo et al.113,114 A sample of 20 subjects with nonspecific shoulder pain and at least one
active and latent MTrP in the infraspinatus muscle were randomized to receive a single
session of TDN treatment to the active MTrP (control group) or the active and latent
MTrPs (experimental group). Pain intensity rated on the numeric pain rating scale, pain
pressure threshold, and grip strength were measured at baseline, immediately following
treatment, and 1 week post treatment. The experimental group that received TDN to an
active and latent MTrP, demonstrated a greater increase in pain pressure threshold that
was statistically significant t(40)= .019, p<0.05, d=1.06 compared to the control
group.113,115 The effect size was also large, suggesting a meaningful difference in
mechanosensitivity between groups.113,115,116
Drawing upon the importance of appropriately matched interventions,
Koppenhaver et al reported on a quasi-experimental study in which 66 subjects diagnosed
with mechanical low back pain received one TDN treatment.83,116-118 Outcome measures
were Oswestry Disability Index (ODI), pain pressure threshold (PPT), and ultrasound
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imaging of the lumbar multifidus thickness at rest and contracted. Measurements were
taken at baseline, immediately following treatment, and one week later. The sample of
subjects was divided in to responders and non-responders based on a clinical
improvement score of 30% change in ODI after one week.116
The authors reported significant improvement in muscle contraction thickness and
pain sensitivity at 1 week for responders than non-responders.116 While the change in
muscle contraction thickness and PPT was below the minimal detectable change (MDC
of 11% and 4.3 to 9.8N/cm2 respectively), as reported by the authors, the trend for greater
improvement was observed in the responders group.116 Responders also demonstrated a
one-week mean improvement score of 62.1% on the ODI.116,119 Identification of
responders and non-responders, or those most likely to benefit from TDN treatment may
prove beneficial for future RCT research and especially clinical practice.
A RCT by Arias-Buria and colleagues examined TDN treatment for postoperative shoulder patients, either open reduction for proximal humerus or repair of the
rotator cuff.119 Twenty subjects were randomized to physical therapy group or physical
therapy plus one session of TDN group over the course of one week.119 Subjects that
received TDN experienced statistically greater improvement in activities of daily living
and strength as measured by the Constant-Murley outcome tool.18,21,113,119-121 Despite the
small sample size, this change in function for acute symptoms continues to support a
trend for the inclusion of TDN into physical therapy management.
Evidence to establish the role of TDN in physical therapy management is
growing. There is emerging evidence to support the use of TDN for the shoulder, heel
pain and LBP.18,21,88,89,91,113,120-123 The limited evidence points towards a positive TDN
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treatment effect but maybe not more than placebo in some cases. A more definitive
conclusion may be drawn with research that is adequately powered and appropriately
designed. Identification of those that may benefit most should be a research priority.

PLACEBO CONTROL DISCUSSION
The common argument against TDN is that it is a ritualistic intervention that
causes a placebo or in some cases nocebo effect. The argument for non-specific effects
or stating that an intervention is not better than placebo can be misleading to clinicians
and patients.122,124-126 This is especially true when the intervention is difficult to sham
inertly and methodology is poor.88,89,91,123,127 TDN is an invasive procedure causing
measureable neurophysiologic stimulation and tissue disruption.124-127 A truly inert
intervention serving as the control treatment for TDN may not be possible. A sham
intervention, either a blunt needle or superficial needling insertion, could have a
biological effect on the subject further complicating the argument.
The effects of TDN may be more than placebo. Mayoral and colleagues randomly
assigned 40 subjects to receive either TDN or the placebo controlled treatment described
as superficial cutaneous needle insertion.127 The inclusion criteria for the sample of
subjects included the following: diagnosed with knee osteoarthritis and scheduled for
total knee arthroplasty; presence of MTrPs in the tensor fascia latae, hip adductors,
hamstrings, quadriceps, gastrocnemius, or popliteus.127 The authors did not provide
further description of MTrPs prevalence. All subjects were blinded to the intervention
and placed under anesthesia.127 The control group received a superficial cutaneous needle
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insertion while the treatment group received one bout of TDN to MTrPs prior to total
knee arthroplasty.127
Since the treatment group started with a higher VAS baseline values, a variation
rate was used to measure change.127 The authors reported the TDN group demonstrated
significantly decreased pain intensity in the first month following total knee arthroplasty
compared to control.127 The degree of pain reduction observed in the first month for the
treatment group was the matched by the control group at 6 months.127 Also, the use of
analgesics was significantly reduced in the TDN group as compared to control.18,116,120,127
This unique placebo controlled study suggests that TDN may be effective for
short-term pain control beyond placebo. The application of one treatment in the context
of individuals with longstanding history of pain is also compelling support for TDN use.
However, as the author’s acknowledged, the sample size is small and susceptible to type
two error.127,128The dosage, number, and location of MTrPs were not described in much
detail thus providing very little guidance for clinical use.
Preliminary evidence exists suggesting benefit of TDN intervention in reducing
pain intensity in the short term.18,116,120,127,128 The small number of heterogeneous studies
with small sample sizes provides some reasoning but limited guidance to physical
therapists. However, these shortcomings culminate into hesitant recommendations for
TDN use in clinical practice. This supporting evidence creates an environment not unlike
LBP intervention research before sub grouping subjects.
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BIOMECHANICAL RESPONSE TO NEEDLING
The exact therapeutic mechanism of TDN is unknown. There is likely a
mechanical and neurophysiologic response. Once the needle is inserted into the
myofascia, clinicians will describe a phenomenon of tissue grasp of the needle separate
from a LTR.128,129 Advancing diagnostic techniques have introduced early evidence to
explain the mechanical response to TDN as well as the immediate physiologic changes
that result.
Subcutaneous grasp of the needle has been documented in both animal and human
investigations. This needle grasp can be significant enough to result in “tenting” of the
skin when attempting to remove the needle.128 In fact, the needle pullout force has been
measured to increase by 167% with needle rotational manipulation.129,130 This significant
shift in pullout force required suggests a unique biomechanical change in not only the
muscle but also the subcutaneous layers.
In early investigations using rat models, subcutaneous collagen bundles where
found to be oriented more parallel to each other following needle insertion and
rotation.128,130 This myofascial reorientation caused by mechanical coupling to the needle
may transmit mechanical signals through afferent sensory nerve fibers and also initiate a
local inflammatory response. Manipulation of the needle can include rotation but is often
described as a rapid up and down motion or sparrow pecking.130 Ultrasound elastography
of this needle manipulation has shown tissue displacements of up to 4cm away from the
treatment site.68,130 Tissue displacement via needle sparrow pecking could create a
biomechanical signal or modulation of local afferent sensory input.124,130
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MTrPs theory centers on the presence of abnormal depolarization of motor end
plates creating a localized sarcomere shortening.68,124 Domingo et al investigated the
neuromuscular damage created by needling using animal modeling.124 Multiple axonal
fragmentation including the motor endplate was observed post TDN using
immunohistochemistry stain in the area of puncture.124 During the first 24 hours, electron
microscopy showed myelin disappearance followed by Schwann cell activity at the
synaptic cleft.124Re-innervation following nerve damage was observed at 72 hours.124 An
inflammatory response was also observed within the muscle, after 24 hours.124 Satellite
cellular activity was observed at 72 hours. Myoblasts followed by myotubes and
myofibrillogenesis represented the first step of muscle regeneration.124,131 Complete
tissue regeneration was demonstrated at 1 week.124
An earlier investigation reported a corresponding inhibitory effect observed in the
TDN of rabbits. The spontaneous electrical activity within the MTrP region was
significantly reduced following TDN.131,132 The decreased electrical activity recorded
may be a result of the biomechanical disruption of the motor end plate reported in the
previous animal study.124,132 It is unknown if these results can be applied to human or
pathological tissue. More than likely, a similar biomechanical process is occurring after
TDN in human subjects. Salom-Moreno et al reported significant decrease in spasticity
following TDN in patients who had previously suffered a stroke.32,132 The authors
theorized an intrinsic change occurred citing alteration to the synaptic motor unit and
structural overlap of the sarcomere as a mechanism for this immediate change.32,132
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BIOMECHANICAL STIFFNESS
Skeletal muscle at rest is exceptionally elastic. Independent of contractile activity
a muscle will maintain tension when stretched then return to its original shape. In
comparison, an electrogenic contraction results in tissue shortening and tension
development followed by re-lengthening to original shape when activation ends.32 The
elasticity of skeletal muscle is therefore dependent on the non-contracted state as well as
the contracted state whether it is voluntary or involuntary.32 Stiffness is the measurement
of elasticity and requires the following: an explanation of the type of load; the location
and direction of application; and the type of the deformation.29 The operational definition
of elasticity is the material’s resistance to deformation.29 When a structure demonstrates
highly elastic characteristics it is measurably very stiff.
Muscle and soft tissue are traditionally described in terms of longitudinal
elasticity. This is a source of confusion from a clinical standpoint because flexibility is
then equated to elasticity. In the clinic, a subject with increased flexibility demonstrates
range of motion exceeding functional norms. It is incorrect to state that this is also a
demonstration of increased elasticity.
The measurement of stiffness in a clinical setting is relevant and may contribute
to the development of a more complete model for understanding biomechanics.4 Altered
muscle stiffness, either increased or decreased, has been identified as a possible source
for injury risk and a biomarker for intervention effectiveness.4,35,78 Too much stiffness
may result in injury due to the increased peak forces, loading rates and shock.4 MTrPs are
localized areas of increased stiffness within the muscle but the direct relationship of
MTrPs and injury is not well established and poorly understood. However, MTrPs could
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impact the performance of the muscle and the increased stiffness may contribute to
localized trauma.

MEASUREMENT OF STIFFNESS
The MyotonPRO® device imparts a mechanical perturbation or impulse with a
small probe that is placed on the superficial skin.37 The probes impulse exerted on the
superficial muscle is of short duration (15 milliseconds) and involves a light mechanical
force (up to 0.6 N).79 The device measures the resultant dampened wave oscillation
following the impulse and the biomechanical property of stiffness is calculated using
Young’s modulus. An example of the acceleration graph and formula follows in Figure
2.1.37

Figure 2.1: MyotonPro® measurement waveforms (displacement, velocity,
acceleration).
S

displacement (tissue oscillation);

35

∆S

pre-compression of subcutaneous tissues above the muscle being
measured;

∆l

maximum deformation;

V

velocity of oscillation;

a

acceleration of oscillation;

t

time in millisecond;

tT

start of the mechanical impulse;

a1

maximum acceleration. Maximum tissue resistance to the mechanical
impulse;

t1

the time when maximum deformation was reached;

tr

the time when tissue returned the shape from deformation;

a2

maximum opposite acceleration due to the tissue inertia;

t2

the time when maximum opposite deformation was reached;

a3

maximum acceleration of the second period of oscillation which takes
place due to the restored residual mechanical energy in the tissue being
measured.

Stiffness formula
Biomechanical Stiffness [N/m]: S = amax ∙ mprobe / ∆l
amax = a1 max acceleration
mprobe = probe mass

Measurement of intervention outcomes requires careful consideration of the
validity and reliability of the measurement device. New or novel approaches in clinical
research deserve greater scrutiny. Myotonmetric measurement results are reported with
good to excellent inter and intratester reliability (ICC 0.80-0.99) in individuals with
normal and neurologically abnormal muscle tone.14,80-85 The MyotonPro® has also been
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used to investigate intervention effects of resting skeletal muscle stiffness following
medication to reduce rigidity in Parkinson’s disease.86
An investigation of reliability and validity of the MyotonPro® was conducted using
polymetric gel-based tissue phantoms (Figure 2.2).87 The study results demonstrated
excellent interrater reliability, ICC = 0.99, SEM = 0.42 N/m, MDC = 0.97 N/m.87 The
MyotonPro® was validated using a 100N load cell on each tissue phantom as comparison
with significant positive relationship r=0.96(Figure 2.3).87

Figure 2.2: Intrarater stiffness measurement for 5 tissue phantoms.
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Figure 2.3: Correlation MyotonPRO® stiffness (N/m) to Young’s Modulus (KPa)

The myotonometer has the potential to aid in the diagnosis and treatment outcome
evaluation of multiple pathologies seen in a physical therapy setting. While initial
investigations have demonstrated some promise for clinical utilization of the
MyotonPRO®, robust research investigating measurement properties and clinical utility
is lacking.14,36,87 The inclusion of this measurement approach into current practice
provides objective data that is actionable in the diagnostic and intervention process. The
MyotonPro® measurement may also serve as a clinically meaningful outcome tool. This
handheld device is a safe, non-invasive alternative to more expensive diagnostic
procedures.
Preliminary observations suggest that muscular pathologies and injuries have
unique elastic/stiffness properties that could be characterized with novel imaging
techniques.8-11 Originally reported by Sikdar et al, ultrasound combined with external
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vibration (ultrasound elastography) allowed researchers to quantify tissue stiffness and
change in that stiffness by measuring the speed at which the vibration waveform
travelled.92 Since then more advanced and reliable approaches have developed. SWE uses
the ultrasound beam to record shear waves that propagate perpendicular to the beam
producing a shear modulus.16 The shear modulus represents the stiffness of the tissue.16
SWE has been shown to be valid, and able to reproduce stiffness parameters of
superficial and deep musculoskeletal tissues.9,11,93,94 Recent research has investigated the
use of SWE in skeletal muscle and preliminarily linked local alterations of muscle
stiffness (e.g., “trigger points”) to chronic musculoskeletal pain conditions.17,35,95
Previous studies have found SWE measures to be highly reliable across a wide variety of
muscle groups.133 Previous studies have also reported a strong linear relationship between
muscle shear modulus and muscle force.94,105,134 While SWE demonstrates great promise
as a laboratory research tool, its large size and high cost (greater than $100,000) makes it
unsuitable for translational clinical trials and potential wider adoption throughout
physical therapy.

SUMMARY
The integrated hypothesis proposes the origin of MTrPs may occur following
biomechanical overload of the muscle structure.70 MTrPs are postulated to occur
following biomechanical stress of the muscle which precipitates the development of a
taut band.67 In theory, with MTrPs representing a contracted portion of muscle, the
resultant stiffness measured would be greater than surrounding, non-contracted tissue.
The presence of MTrPs in muscle may give rise to increased tissue stiffness as a result of
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the contracted fibers.28 Recently, the quantification of MTrPs biomechanical stiffness and
the change following TDN has been reported using a SWE.18,20,35 A trend for
improvement following TDN is emerging from more recent investigations but outcome
measurement is often limited to subjective reports of pain and function. Objective in vivo
measurement of the biomechanical structural properties of muscle is a complimentary
approach to current clinical assessment. This investigation will use the MyotonPro® to
characterize the biomechanical stiffness of MTrPs pre and post TDN intervention. This
pragmatic and novel approach may identify a clinically relevant biomarker for trigger
point identification and response of clinical TDN intervention.
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CHAPTER 3 – METHODOLOGY

INTRODUCTION
Measurement of soft tissue stiffness before and after trigger point dry needling
(TDN) may prove to be a useful, and valid approach to quantifying physiological change.
This chapter provides the description of the research design and methodology to measure
biomechanical stiffness of a myofascial trigger point (MTrP) before and after TDN. The
inclusion and exclusion criteria for subject participation and method of recruitment is
described. The instrumentation and procedure for data collection and analysis are
presented. The specific aims for phase one are: investigate the test retest reliability of the
MyotonPRO® and shear wave elastography (SWE) measurement during three separate
conditions of muscle contraction; investigate the concurrent validity of the MyotonPRO®
comparative to the SWE during three separate conditions of muscle contraction.
This study consisted of two phases conducted at AMEDD Center and School, San
Antonio, TX and at Bradley University, Peoria, IL. In the first phase, reliability and
concurrent validity of the MyotonPRO® and SWE was investigated in 30 asymptomatic
individuals. The first phase was conducted at AMEDD Center and School utilizing the
available SWE machine and MyotonPRO® instrumentation. The second phase was
conducted at Bradley University using the MyotonPRO® to investigate biomechanical
stiffness change following TDN in 60 subjects with palpable muscle MTrPs.
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INSTRUMENTATION
All SWE images were obtained using a Supersonic Aixplorer® ultrasound system
(Supersonic Imagine®, Aix-en-Provence, France) with a 50mm 10-2 MHz linear array.
The elastographic image is a grey-scale (B-mode) image with a color overlay that
represents the shear modulus in kPa. The mean shear modulus within the selected area of
interest is recorded as the SWE stiffness value. SWE measurement uses focused
ultrasound radiation forces causing a wave to travel horizontal to the point of application
through tissue, to estimate material properties.135 The measurement estimates Young’s
modulus based on the shear wave velocity of ultrasound propagation.135As wave velocity
increases the Young’s modulus increases, indicating a stiffer material.16 The Young’s
modulus (kPa) is measured in real time with acquisition lasting less than 6 seconds.135
Biomechanical stiffness measurements were obtained using the MyotonPRO®
(Myoton® AS, Tallinn, Estonia) by applying a mechanical impulse to the skin, which is
transmitted to the underlying soft tissue and muscle (0.58 N for 15 ms).37,79 The
mechanical impulse compresses the tissue and muscle responds by a damped natural
oscillation. The oscillation of the muscle is recorded by an accelerometer located at the
probe end. The peak acceleration (p) is measured after the termination of the impulse.
The acceleration signal is integrated twice to determine the displacement signal. The
force generated by the mass of the probe is proportional to the acceleration of the probe.
The dynamic stiffness (S) in MyotonPRO® is expressed as S = mp/d, where m is the
mass of the probe (18 g), p is the maximum amplitude of the oscillation in the
acceleration signal, and d is the amplitude of the displacement signal at the end of the
impulse time.87
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The stiffness parameters are calculated from the acceleration signal and are comparable
to shear modulus in kPa.

PHASE ONE: RESEARCH DESIGN
The purpose of the first phase was to investigate the reliability and concurrent
validity of the MyotonPRO® to the criterion of SWE over increasing muscular
contractions. This first phase was a prospective single group design with repeated
measures. Subjects were assigned to one cross sectional group. Separate SWE and
MyotonPRO® stiffness measurements were collected in a randomized order on the
infraspinatus muscle, erector spinae muscles, and gastrocnemius muscle. Measurements
of the individual muscles (infraspinatus, multifidus, and gastrocnemius) were acquired on
the left side at rest, during sub-maximal isometric contraction, and during a maximal
voluntary isometric contraction (MVIC) for each muscle as described below. The MVIC
was identified by the maximum isometric value recorded by a dynamometer during a
muscle test. The 40% and 80% of the MVIC represented sub-maximal contraction as
recorded. For all conditions, 3 measures were taken and averaged for data analysis.

SAMPLE SIZE ESTIMATION
Power analysis was performed using z-transformation to estimate sample size for
correlation. With 80% power; 95% significance level; to detect a simple correlation r
(r=0.5); the required sample size is 29.97 Total enrollment of 30 subjects will provide
adequate precision around reliability estimates (intraclass correlation coefficients [ICC]
with 95% CIs).
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PARTICIPANT SELECTION AND RECRUITMENT
A sample of 30 asymptomatic subjects was recruited from all Department of
Defense beneficiary categories (active duty, retiree, dependents, etc.) between the age of
18 and 65 years of age. Subject selection was equitable without limitations to race,
ethnicity or gender. Potential participants responded to word of mouth or flyer posted
around Joint Base San Antonio. Prescreening recruitment of potential participants
consisted of a brief description of the study and inclusion/exclusion criteria. Interested
participants reported their gender and age and then simply stated whether or not they
believed that they meet all of the inclusion/exclusion criteria for study participation.

INCLUSION AND EXCLUSION CRITERIA
Subjects must meet all the following criteria.
Inclusion criteria (all of the following)
a) Age 18 to 65 years
b) Free from musculoskeletal pain for 6 months
c) Able to perform repeated maximal isometric muscle contraction in the upper and
lower quarter.
d) Full active range of motion of the upper and lower quarter.
Exclusion criteria (any of the following)
a) Current musculoskeletal impairment
b) Body mass index > 31
c) Recent (6 month) history of surgery
d) History of systemic inflammatory disease
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e) Known pregnancy
f) Inability to lie prone
g) Inability to read and understand English

CONSENT PROCESS
The study Primary Investigator (PI), and Research Assistant conducted the consent
process in the presence of a witness with the subject utilizing the approved informed consent
in a private setting. The investigator informed the subject that the study involves research
and explain the purpose and procedures entailed in this study. Furthermore, the subjects were
informed of the approximate amount of subjects involved in the study. In addition, any
foreseeable risks, discomforts, and benefits were explained. The voluntary nature of the
participation was stressed. Study personnel will remind subjects, throughout their
participation, that they may elect to withdraw from the study at any time. Subjects were
assured that a decision not to participate will have no effect on their military status or ability
to access health care; yet, if the subject chooses to participate he/she was informed that all
records identifying the subject are maintained confidentially by the PI in a password
protected electronic file and all hard copies are maintained in a locked file cabinet that only
the PI and study team have access to. Subjects electing to withdraw from the study will not
participate in any data collection or other procedures associated with this study. The
investigative team may terminate a subject’s participation in the study at any time he/she
feels this to be in the subject’s best interest (i.e., safety, health, etc). Moreover, subjects were
provided with the appropriate contact information of whom to speak to about their rights and
whom to speak with should the subject have any questions.
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Subjects were given ample time to ask questions, read and understand the consent
form and take it home (if he/she chooses) so the research can be discussed with friends and
family prior to participation. Upon completion of the informed consent process and after all
concerns were addressed the subject, the individual obtaining consent along with a partial
witness signed the approved IRB consent forms. A copy of the signed documents was offered
to the subject, and the original signed document was placed in the subject’s study record. The
informed consent process occurred and all parties prior to any/all study related procedures
signed the informed consent document.

SUBJECT SCREENING PROCEDURES
Participants satisfying all inclusion and exclusion criteria were enrolled in the study.
After providing informed consent, volunteers received a short screening examination. The
screening examination consisted of answering questions regarding their medical history and
current symptoms and a brief physical examination. Anthropometric data (height, weight,
BMI) was collected via clinical measurement. The focused physical examination consisted of
the following:
1. Visual inspection
2. Functional active range of motion of the shoulder (reaching hand behind head
and reaching hand behind back), and lower quarter (squat, toe/heel walk).
3. Active range of spinal range of motion in standing: flexion, extension, side
bending. Lumbar spine clearing maneuvers (quadrant test and posterior to
anterior pressure to the spine).
4. Resisted shoulder, low back, and calf manual muscle test.
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DATA COLLECTION PROCEDURE
For participants enrolled in the first phase of the study, the initial visit included a
demographic and medical history questionnaire. Basic demographic information such
age, sex, ethnicity, past medical history, height, and body mass was collected to describe
the participant sample. The screening examination was followed by ultrasonic SWE and
MyotonPRO® measurements of muscle stiffness/elasticity.

MEASUREMENT POSITIONS
Infraspinatus: The participant was seated in an upright position with the left side
of the body against a wall, in a straight back chair (Figure 3.1). The arm positioned by the
side in neutral, elbow in 90 degrees flexion, and wrist in neutral. The HHD was anchored
to the wall so that the pad contacted the forearm proximal to the distal radial styloid
process. Participants were instructed to eternally rotate their humerus with the forearm
against the HHD with the trunk in an upright position. The MyotonPRO® and SWE
measurements were taken at two fingers breadth below the center spine of the left scapula
(Figure 3.1).136
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Figure 3.1: Subject positioning for isometric infraspinatus contraction and
measurement location outlined two fingers breadth below the center spine of the left
scapula

Erector spinae: The participant was placed in prone on a full length, padded table
with arms resting at their sides or hanging off the table at approximately 90 degrees
shoulder flexion. Three adjustable straps where used to stabilize the participant to the
table (Figure 3.2). One strap was placed at the level of the greater trochanter across the
hips to secure the pelvis. The second strap was placed at the knees superior to the
popliteal crease to secure the lower extremities. A third strap fixated the HHD at thoracic
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level 7 spinous process, and the strap was anchored to the table. A towel was used
between the HHD and T7 spinous process for subject comfort. The MyotonPRO® and
SWE location for measurement was standardized to the lumbar level 4 on the left side, by
bisecting the muscle bulk lateral to the spinous process. The measurement location was
outlined while at rest on the palpable muscle bulk one-finger breadth from the spinous
process (Figure 3.2).136

Figure 3.2: Subject positioning and belt placement for erector spinae isometric
contraction. Erector spinae measurement location with iliac crest and L4 spinous process
identified with rectangle transducer outlined on the palpable muscle belly.
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Gastrocnemius: The participant was prone, shoes off with feet hanging
unsupported off edge of the table, and knees resting in 0 degrees extension. The trunk and
lower extremities were anchored to the table by a strap just above the popliteal crease and
across the pelvis at the level of the greater trochanters. The ankle position was maintained
at 0 degree neutral for isometric with the dynamometer pad placed at the first metatarsal
head and HHD anchored to the wall (Figure 3.3). Measurements were taken at four
fingerbreadths below popliteal crease in the belly of the left medial gastrocnemius
(Figure 3.3).136
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Figure 3.3: Subject positioning for isometric gastrocnemius contraction in prone. Medial
gastrocnemius measurement location identified four fingerbreadths below popliteal
crease in the belly of the left medial gastrocnemius.

MEASUREMENT
SWE and MyotonPRO® techniques were used to measure muscle stiffness under
3 conditions: rest and 2 intensity levels of isometric contraction. For the rest condition,
the participants were instructed to relax during a 30-second period while measures of
SWE and MyotonPRO® stiffness were measured. Participants then performed 2
repetitions of a maximum voluntary isometric contraction (MVIC) to determine and set a
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submaximal threshold. The submaximal thresholds were viewed as clinically applicable
and functional in respect to activities of daily living. A 40% and 80% MVIC levels were
chosen to allow for the <6 seconds contraction needed to acquire a SWE image.16 40%
and 80% goals were set with +/- 2.5% threshold range to account for observed variance in
contraction control.137 Participants were instructed to perform the designated contraction
within the predetermined range for no longer than 6 seconds. Participants viewed the
amount of force applied against the HHD via a display on an external monitor placed
directly in their field of view. Three repeated measurements were conducted for both the
SWE and MyotonPRO® at each muscle location for each contraction state (resting, 40%,
80%). The order of muscle, contraction intensity, and measurement device was
randomized. Example SWE measurement image of 40% MVIC in the infraspinatus,
erector spinae, and gastrocnemius is provided (Figure 3.4). The stiffness color scale
shown to the left of the figure with red representing higher magnitude of stiffness and
blue lower magnitude of stiffness.
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Figure 3.4: Example SWE measurement image of 40% MVIC in the infraspinatus,
erector spinae, and gastrocnemius.
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DATA ANALYSIS
Statistical analyses were performed using SPSS 22.0 software (IBM SPSS Inc,
Armonk, NY). Multiple one way repeated measures analysis of variance (ANOVA) with
Bonferroni post hoc was conducted to evaluate for differences in muscle stiffness
between the three levels of muscle contraction (rest, 40% MVIC, and 80% MVIC) for
each measurement tool (MyotonPRO® and SWE) and for each muscle (infraspinatus,
erector spinae, and gastrocnemius). Pearson’s product-moment correlation was
conducted to assess the relationship between stiffness measured by the MyotonPRO®
and SWE (ROI 5mm and 10mm) in three muscles during rest, 40%MVIC, and 80%
MVIC. Intra-rater reliability was calculated using a two way mixed model, intraclass
correlation coefficient single measure and a mean of 3 measures. The reliability for a
single measurement was estimated using the first two measurement variables and the
“single measures” output from SPSS (model 3,1).102 The reliability when using a mean of
3 measurements was estimated using the first 3 measurement variables and the “average
measures” output from SPSS (model 3,3).102 Statistical significance was set a priori for
all analyses at p< .05. The following guideline was used to determine the strength of the
ICC: <0.25 no correlation; 0.25-0.5 fair; 0.5-0.75 moderate to good; and >0.75 good to
excellent correlation.103
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PHASE TWO: RESEARCH DESIGN
This second phase was a case series multi group design with repeated measures.
The purpose of phase two was to investigate the immediate and short-term (24hrs)
biomechanical effect of dry needling a latent myofascial trigger point in the infraspinatus,
erector spinae, or gastrocnemius of healthy subjects. A sample size of 60 (20 per group)
was based off reported latent trigger point prevalence in a healthy population.101 60
healthy individuals between the ages of 18 and 65, without musculoskeletal complaints,
and who have palpable, latent MTrPs were recruited via word of mouth from Bradley
University and assigned to a group. The 3 groups were formed by the location of the
MTrP: shoulder (infraspinatus), calf (gastrocnemius), or low back (erector spinae).
Subjects with MTrPs in more than one of the three muscles were only assigned to one
group. Participants were excluded if they have any precautions to TDN treatment
(anticoagulant medications, bleeding disorders, known pregnancy) or have signs or
symptoms requiring medical referral. Primary study variable was biomechanical stiffness.
Stiffness was measured using the MyotonPRO® instrumentation. Baseline measurements
were taken followed by TDN to the latent MTrPs. Follow up stiffness measurements
were collected immediately after TDN and again at 24 hours post TDN intervention.
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INCLUSION AND EXCLUSION CRITERIA
Subjects must meet all the following criteria. The inclusion criteria for study
participant eligibility in this study includes:
a. Age 18 to 65 years
b. Body mass index of 30 or less
c. Reported good general health
The following exclusion criteria for study participant ineligibility in this study includes:
a. Infectious disease (e.g. HIV, Hepatitis B, Hepatitis C)
b. Active systemic disease (e.g. cancer, diabetes, peripheral vascular disease,
rheumatoid arthritis, lupus erythema, lymphedema, fibromyalgia, epilepsy)
c. Any surgery in the last 12 months
d. Local infection, wound, or compromised immune system
e. Neurologic condition (e.g. impaired or decreased sensation or pain perception)
f. Current lower limb musculoskeletal injury
g. Lumbar radiculopathy or current low back pain
h. Trigger point injection, dry needling, or acupuncture in the past 6 months
i. Medications that affect muscle function including: nonsteroidal antiinflammatories; statins; anti-coagulants; and muscle relaxers
j. Pregnancy
k. Needle phobia
l. Unable or unwilling to provide consent
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CONSENT PROCESS
Subjects were enrolled in the study once informed consent was provided. The
study PI conducted the consent process in the presence of a witness with the subject
utilizing the approved informed consent in a private setting. The investigator informed
the subject that the study involved research and explained the purpose and procedures
entailed in this study. Furthermore, the subjects were informed of the approximate
amount of subjects involved in the study. In addition, any foreseeable risks, discomforts,
and benefits were explained. The voluntary nature of the participation was stressed.
Study personnel reminded subjects, throughout their participation, that they might elect to
withdraw from the study at any time. Subjects who were students of the university were
assured that a decision not to participate has no effect on their academic status; yet, if the
subject chooses to participate he/she was informed that all records identifying the subject
are maintained confidentially by the PI in a password protected electronic file and all
hard copies are maintained in a locked file cabinet that only the PI has access to. Subjects
electing to withdraw from the study did not participate in any data collection or other
procedures associated with this study. The investigative team may terminate a subject’s
participation in the study at any time he/she feels this to be in the subject’s best interest
(i.e., safety, health, etc). Moreover, subjects were provided with the appropriate contact
information of whom to speak to about their rights and whom to speak with should the
subject have any questions.
Subjects were given ample time to ask questions, read and understand the consent
form and take it home (if he/she chooses) so the research can be discussed with friends and
family prior to participation. Upon completion of the informed consent process and after all
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concerns were addressed the subject, the individual obtaining consent signed the approved
IRB consent forms. A copy of the signed documents was offered to the subject, and the
original signed document was placed in the subject’s study record. The informed consent
process occurred and all parties prior to any/all study related procedures signed the informed
consent document.

SUBJECT SCREENING PROCEDURE
Participants satisfying all inclusion and exclusion criteria were enrolled in the study.
After providing informed consent, volunteers received a short screening examination. The
screening examination will consist of answering questions regarding their medical history
and current symptoms and a brief physical examination. Anthropometric data (height,
weight, BMI) was collected via clinical measurement. The focused physical examination
consisted of the following:
1. Visual inspection
2. Functional active range of motion of the shoulder (reaching hand behind head
and reaching hand behind back), and lower quarter (squat, toe/heel walk).
3. Active range of spinal range of motion in standing: flexion, extension, side
bending. Lumbar spine clearing maneuvers (quadrant test and posterior to
anterior pressure to the spine).
4. Resisted shoulder, low back, and calf isometric manual muscle test.
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DATA COLLECTION PROCEDURE
After a standardized screening history and physical examination, MyotonPRO®
measurement assessments were made of the latent MTrP while in a resting prone
position. Identification of the latent MtrP will be located in the gastrocnemius,
infraspinatus, and erector spinae of the lumbar spine. All needling treatment was
performed with FDA approved (FDA regulation # 880.5580) disposable 0.30 x 50-60 mm
stainless steel Seirin J-type needles (Seirin, Japan). Needles were stored in the original
sterile packaging from the manufacturer until immediately before use. To assist in the
reduction of infection risk and protection of the participants, the site was cleaned with
alcohol prior to treatment and PI performing the needling treatment wore gloves and
handled needles using aseptic techniques. Each needle insertion used a “pistoning” or
“sparrow pecking” technique. Once inserted through the skin and into the muscle to a
depth of less than 3 centimeters, the pistoning technique was used for 1 minute. Any
incident of a localized twitch response was recorded. MyotonPRO® measurements were
collected to evaluate the immediate and short-term effects of TDN treatment on the
biomechanical stiffness, immediately after treatment, and again at 24 hours.
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DATA ANALYSIS
Statistical analysis was performed using SPSS 22.0 software (IBM SPSS Inc,
Armonk, NY). Descriptive statistics was performed to describe the sociodemographic and
health characteristics of the entire sample. Means, standard deviations, mean differences,
and 95% confidence intervals were computed for continuous data. One way repeated
measures analysis of variance (ANOVA) with Bonferroni post hoc was conducted to
evaluate for difference in muscle stiffness pre and post TDN (immediately and 24 hours).
The analysis was repeated in a subgroup of individuals that demonstrated a localized
twitch response during TDN.

FUNDING FOR THE STUDY
This work was funded by the Army Medical Department Advanced Technology
Initiative (AAMTI), through the Telemedicine and Advanced Technology Research
Center (TATRC). This work was supported by the Telemedicine and Advanced
Technology Research Center (TATRC) at the US Army Medical Research and
Materiel Command.

SUMMARY
In this chapter, the methodology for the research proposal was detailed. TDN
clinical effectiveness and the role of biomechanical stiffness measurement are yet to be
elucidated. The project entailed two separate phases to answer the following research
questions: What is the concurrent validity of the MyotonPRO® as compared to the
criterion of SWE in the measurement of biomechanical stiffness in the infraspinatus,
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erector spinae, or gastrocnemius of healthy subjects over increasing muscle contraction?
What is the reliability of the MyotonPRO® measurement? What is the biomechanical
response of a latent MTrP to TDN in the infraspinatus, erector spinae, or gastrocnemius
measured using the MyotonPRO®?
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CHAPTER 4: RESULTS

INTRODUCTION
This chapter will discuss the results for investigating the reliability and validity of
biomechanical measurement using shear wave elastography (SWE) and the
MyotonPRO®. We will then discuss the results of trigger point dry needling (TDN)
latent myofascial trigger points (MTrPs) and the effects it has on measured stiffness using
the MyotonPRO®. Descriptive statistics, including measures of central tendency (means)
and dispersion (95% confidence interval (CI)) for continuous variables were calculated to
summarize the data. There were no dropouts by subjects participating in the study.

SPECIFIC AIM 1
The first specific aim was to investigate the reliability and concurrent validity of
the MyotonPRO® to the criterion of SWE over increasing muscular contractions. We
hypothesized that the biomechanical measurement across increasing muscle contractions
would demonstrate a trend of increasing stiffness. The 2 measurement devices would
demonstrate a positive correlation.
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ANALYSIS SPECIFIC AIM 1
A sample of 30 subjects (13 female, 17 male) was enrolled in the study. Data
presented are mean (standard deviation). The mean age was 28 (5.76) with a mean height
of 1.74 (0.10) meters and mean mass of 78.69 (14.77) kilograms. The sample’s mean
body mass index (BMI) was 25.67 (2.38). Table 4.1 summarizes this demographic data.

Table 4.1 Demographic Data (n=30)
Characteristic
Age (years)
Height (m)
Mass (kg)
BMI (kg/m2)
Sex (n)
Female
Male

Value
27.87 (5.76)
1.74 (0.10)
78.69 (14.77)
25.67 (2.38)
13
17

Values represent mean (standard deviation)
unless otherwise indicated.
BMI: Body Mass Index

Stiffness was measured across three levels of muscle contraction using both the
shear wave ultrasound and the MyotonPRO® in all subjects. Shear wave ultrasound
measurements were further separated into two different sized regions of interest (ROI),
5mm and 10mm. Results of the statistical tests follow below.
The three levels of muscle contraction elicited statistically significant changes in
stiffness as measured by the MyotonPRO® (N/m) in all three muscles (Table 4.2). The
MyotonPRO® demonstrated a low coefficient of variation for resting conditions (2-3%).
The MyotonPRO® coefficient of variation increased during active muscle contraction but
still remained low, ranging from 4-9%. Infraspinatus contraction was statistically
significantly different at the different time points during rest, 40%, and 80% contraction
intensities, F(2,58) = 58.34, p < .001. Erector spinae contraction was statistically
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significantly different at the different time points during rest, 40%, and 80% contraction
intensities, F(2,58) = 20.00, p < .001. Gastrocnemius contraction was statistically
significantly different at the different time points during rest, 40%, and 80% contraction
intensities, F(2,58) = 48.65, p < .001.
MyotonPRO® data presented below are mean (95% CI) followed by the mean
difference (95% CI) (Table 4.2). MyotonPRO® infraspinatus stiffness (N/m) increased
from 265.8 (248.9, 282.6) at rest to 490.7 (416.6, 564.9) at 40% MVIC, a statistically
significant increase of 225.0 (141.8, 308.2), p < .001. The measured stiffness increased
from 490.7 (416.6, 564.9) at 40% MVIC to 576.5 (491.6, 661.4) at 80% MVIC, a
statistically significant increase of 85.78 (53.21, 118.33), p < .001.
MyotonPRO® erector spinae stiffness increased from 289.4 (259.3, 319.5) at rest
to 418.1 (332.9, 503.3) at 40% MVIC, a statistically significant increase of 128.7 (53.9,
203.6), p < .001. The measured stiffness of 418.1 (332.9, 503.3) at 40% MVIC increased
to 469.3 (367.7, 503.3) at 80% MVIC, a statistically significant increase of 51.2 (5.3,
97.0), p = .025.
Gastrocnemius resting stiffness increased from 326.2 (299.3, 353.0) to 588.9
(491.7, 686.2) at 40% MVIC, a statistically significant increase of 262.8 (154.4, 371.1), p
< .001. The measured stiffness of 588.9 (491.7, 686.2) at 40% MVIC increased to 658.0
(558.5, 757.6) at 80% MVC, a statistically significant difference of 69.1 (37.8, 100.4), p
< .001.
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Table 4.2 MyotonPRO® muscle stiffness values stratified by contractile condition.
Contraction condition
Infraspinatus resting
Infraspinatus 40% MVIC
Infraspinatus 80% MVIC
Erector spinae resting
Erector spinae 40% MVIC
Erector spinae 80% MVIC
Gastrocnemius resting
Gastrocnemius 40% MVIC
Gastrocnemius 80% MVIC

Mean (95% CI)
265.8 (248.9, 282.6)
490.7 (416.6, 564.9)*
576.5 (491.6, 661.4)*
289.4 (259.3, 319.5)
418.1 (332.9, 503.3)*
469.3 (367.7, 503.3)*
326.2 (299.3, 353.0)
588.9 (491.7, 686.2)*
658.0 (558.5, 757.6)*

CV%
3%
9%
8%
3%
6%
6%
2%
5%
4%

Mean Difference (95%CI)
225.0 (141.8, 308.2)
85.8 (53.2, 118.3)
128.7 (53.9, 203.6)
51.2 (5.3, 97.0)
262.8 (154.4, 371.1)
69.1 (37.8, 100.4)

*p < 0.05 significant difference between all measured contraction conditions

The SWE measurement for 5mm and 10mm demonstrated the same coefficient of
variation. This coefficient of variation was ranged between 7 and 30%. The resting
measure demonstrated a similar trend for being lower than the active measurement.
Overall, the variation was greater than observed in the MyotonPRO®.
The shear elastic modulus, as measured by shear wave elastography, was
statistically different for gastrocnemius 5mm ROI (Table 4.3) across the three contraction
conditions, F(2,58) = 61.18, p < .001. There were no significant differences between
contraction conditions for the infraspinatus or the erector spinae using the 5mm ROI. The
SWE shear elastic modulus using 10mm ROI was statistically significant for 40% and
80% MVIC, as compared to the resting condition in the erector spinae muscle F(2,58) =
18.64, p < .001. There was no significant difference between the 40% and 80% MVIC.
There were no differences between contraction conditions for the gastrocnemius and
infraspinatus (Table 4.3).
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The 5mm ROI gastrocnemius resting stiffness (kPA) group mean (95% CI) was
23.5 (19.9, 27.2), 40% MVIC was 66.0 (54.9, 77.1), and 80% MVIC was 86.8 (73.0,
100.6). The mean difference between gastrocnemius rest to 40% was 42.5 (28.6, 56.3),
P<.001. The mean difference between gastrocnemius 40% and 80% was 20.8 (7.4, 34.2),
P<.001. The mean difference between gastrocnemius rest and 80% was 63.3 (46.3, 80.2),
P<.001.
Table 4.4, 10mm ROI erector spinae muscle resting stiffness (kPA) group mean
(95% CI) was 16.5 (14.1, 18.9), 40% MVIC was 25.9 (21.0, 30.7), and 80% MVIC was
29.7 (24.4, 35.0). The mean difference between erector spinae rest to 40% was 9.4 (3.6,
15.1), P=.001. The mean difference between erector spinae rest and 80% was 13.2 (7.0,
19.4), P<.001.
Table 4.3 Shear wave elastography muscle stiffness (kPA) values stratified by
contractile condition. 5mm Region of interest.
Contraction condition
Mean (95%CI)
CV% Mean Difference (95%CI)
Infraspinatus resting
23.9 (18.8, 29.0)
19%
Infraspinatus 40% MVIC
29.4 (24.7, 34.2)
20%
5.6 (-0.4, 11.5)
Infraspinatus 80% MVIC
27.1 (23.6, 30.6)
22%
2.3 (-2.4, 7.0)
Erector spinae resting
23.5 (18.2, 28.7)
16%
Erector spinae 40% MVIC
29.8 (23.5, 36.0)
30%
6.4 (-2.3,15.1)
Erector spinae 80% MVIC
28.8 (23.1, 34.5)
31%
-1.0 (-6.7, 4.7)
Gastrocnemius resting
23.5 (19.9, 27.1)
7%
Gastrocnemius 40% MVIC
66.0 (54.9, 77.1)*
22%
42.46 (28.58, 56.34)
Gastrocnemius 80% MVIC
86.8 (73.0, 100.6)* 20%
20.81 (7.42, 34.21)
*p < 0.05 significant difference between all measured contraction conditions

Table 4.4 Shear wave elastography muscle stiffness (kPA) values stratified by contractile
condition. 10mm Region of interest.
Contraction condition
Mean (95%CI)
CV%
Mean Difference (95%CI)
Infraspinatus resting
27.7 (23.7, 31.7)
19%
Infraspinatus 40% MVIC
29.8 (25.5, 34.1)
20%
2.0 (-3.1, 7.1)
Infraspinatus 80% MVIC
29.1 (26.2, 31.9)
22%
-0.7 (-4.4, 3.0)
Erector spinae resting
16.5 (14.1, 18.9)
16%
Erector spinae 40% MVIC
25.9 (21.0, 30.7)**
30%
9.4 (3.6, 15.1)
Erector spinae 80% MVIC
29.7 (24.4, 35.0)**
31%
3.9 (-1.0, 8.8)
Gastrocnemius resting
18.2 (15.5, 21.0)
7%
Gastrocnemius 40% MVIC
55.6 (46.7, 64.6)*
22%
37.4 (25.6, 49.2)
Gastrocnemius 80% MVIC
79.6 (68.3, 91.0)*
20%
24.0 (12.9, 35.1)
*p < 0.05 significant difference between all measured contraction conditions
**p < 0.05 significant difference between measured resting contraction intensity only
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The following guideline was used to determine the strength of the ICC: <0.25 no
correlation; 0.25-0.5 fair; 0.5-0.75 moderate to good; and >0.75 good to excellent
correlation.103 Intrarater reliability estimates were excellent (ICC > 0.93) for all
MyotonPRO® measures for both single measures and based on an average of 3 measures
(Table 4.5). Intrarater reliability estimates for the SWE measures were lower when using
a single measure and improved based on a mean of 3 measurements (ICC = 0.56 to 0.98)
in each muscle across all contraction conditions (Table 4.5).
Table 4.5 Intrarater Reliability
Number of Measurements

Infraspinatus resting
Single
Mean of 3
Infraspinatus 40% MVIC
Single
Mean of 3
Infraspinatus 80% MVIC
Single
Mean of 3
Erector spinae resting
Single
Mean of 3
Erector spinae 40% MVIC
Single
Mean of 3
Erector spinae 80% MVIC
Single
Mean of 3
Gastrocnemius resting
Single
Mean of 3
Gastrocnemius 40% MVIC
Single
Mean of 3
Gastrocnemius 80% MVIC
Single
Mean of 3

MyotonPRO®
ICC3,k (95% CI)

Shear Wave Elastography
5mm ROI
10mm ROI
ICC3,k (95% CI)
ICC3,k (95% CI)

0.95 (0.90, 0.97)
0.98 (0.97, 0.99)

0.79 (0.65, 0.88)
0.92 (0.85, 0.96)

0.74 (0.58, 0.85)
0.89 (0.80, 0.95)

0.93 (0.88, 0.97)
0.98 (0.96, 0.99)

0.67 (0.48, 0.81)
0.86 (0.74, 0.93)

0.74 (0.58, 0.86)
0.90 (0.81, 0.95)

0.93 (0.88, 0.97)
0.98 (0.96, 0.99)

0.30 (0.07, 0.53)
0.56 (0.19, 0.78)

0.46 (0.23, 0.66)
0.72 (0.48, 0.86)

0.99 (0.97, 0.99)
1.0 (0.99, 1.0)

0.80 (0.66, 0.89)
0.92 (0.85, 0.96)

0.71 (0.54, 0.84)
0.88 (0.78, 0.94)

0.97 (0.94, 0.98)
0.99 (0.98, 0.99)

0.57 (0.36, 0.74)
0.80 (0.63, 0.90)

0.56 (0.35, 0.74)
0.79 (0.62, 0.89)

0.99 (0.98, 0.99)
1.0 (0.99, 1.0)

0.60 (0.40, 0.76)
0.81 (0.66, 0.91)

0.55 (0.34, 0.73)
0.78 (0.60, 0.89)

0.99 (0.98, 1.0)
1.0 (0.99, 1.0)

0.91 (0.85, 0.96)
0.97 (0.95, 0.99)

0.95 (0.91, 0.97)
0.98 (0.97, 0.99)

0.97 (0.95, 0.99)
0.99 (0.98, 1.0)

0.72 (0.56, 0.84)
0.89 (0.80, 0.94)

0.83 (0.72, 0.91)
0.94 (0.87, 0.97)

0.98 (0.97, 0.99)
0.99 (0.99, 1.0)

0.69 (0.51, 0.82)
0.87 (0.76, 0.93)

0.69 (0.52, 0.82)
0.87 (0.76, 0.93)

MVIC: Maximum voluntary isometric contraction. ROI: Region of interest
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Scatter plots were created comparing the measurement techniques across each
muscle showed a positive correlation between MyotonPRO® and SWE (Figure 4.1-4.6).
Pearson’s correlation coefficient was conducted to determine the magnitude of the
correlation between both measures. The following guideline was used to determine the
strength of the association.138 A small correlation ranges 0.1 to 0.3. A moderate
correlation ranges between 0.3 and 0.5. A strong correlation is greater than 0.5. The
correlation between measures was strong for gastrocnemius (r=0.71). (Table 4.6)

Figure 4.1: Scatter plot of SWE ROI 5mm and MyotonPRO® measurement across 0%,
40%, and 80% MVIC in the infraspinatus.
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Figure 4.2: Scatter plot of SWE ROI 10mm and MyotonPRO® measurement across 0%,
40%, and 80% MVIC in the infraspinatus.

Figure 4.3: Scatter plot of SWE ROI 5mm and MyotonPRO® measurement across 0%,
40%, and 80% MVIC in the erector spinae.
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Figure 4.4: Scatter plot of SWE ROI 10mm and MyotonPRO® measurement across 0%,
40%, and 80% MVIC in the erector spinae.

Figure 4.5: Scatter plot of SWE ROI 10mm and MyotonPRO® measurement across 0%,
40%, and 80% MVIC in the gastrocnemius.
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Figure 4.6: Scatter plot of SWE ROI 5mm and MyotonPRO® measurement across 0%,
40%, and 80% MVIC in the gastrocnemius.

Table 4.6: Pearson’s correlation coefficient
between MyotonPRO® and Shear Wave
Elastography SWE
Muscle (0%, 40%, 80% MVIC)
Infraspinatus
Erector spinae
Gastrocnemius
*Correlation is significant p< 0.05

ROI
5mm

ROI
10mm

0.35*
0.40*
0.71*

0.23*
0.51*
0.71*

MVIC: Maximum voluntary isometric contraction.
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SPECIFIC AIM 2
The second specific aim of this study was to investigate the biomechanical effects
of MTrPs to TDN intervention using the MyotonPRO®. We hypothesized that an
immediate decrease in MTrP stiffness would occur following TDN.

ANALYSIS SPECIFIC AIM 2
The second phase of this study investigated the change in stiffness following
trigger point dry needling (TDN) in a latent myofascial trigger point (MTrP) in one of
three muscles (infraspinatus, erector spinae, and gastrocnemius). A sample of 60 subjects
(31 female, 29 male) was enrolled in the study. Subjects were assigned in groups of 20
based on the location of the MTrP (infraspinatus, erector spinae, gastrocnemius).
Data presented are mean (standard deviation). The mean age for the sample was
23 (2.99) years with a mean height of 1.74 (0.09) meters and mean mass of 74.02 (13.63)
kilograms. The sample’s mean body mass index (BMI) was 24.17 (2.90). Table 4.7
summarizes this demographic data.
Table 4.7 Demographic Data
Characteristic
Age (years)
Height (m)
Mass (kg)
BMI (kg/m2)
Sex (n)
Female
Male

Value
23 (2.99)
1.74 (0.09)
74.02 (13.63)
24.17 (2.90)
31
29

Values represent mean (standard deviation) unless otherwise indicated.
BMI: Body Mass Index
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Muscle stiffness mean measurement decreased immediately after TDN in all the
groups (Table 4.8). The gastrocnemius MTrP group significantly decreased immediately
after TDN, F(2,38) =12.62, p< 0.001. The infraspinatus and erector spinae stiffness
decrease was not statistically significant. All groups demonstrated a mean increase in
stiffness 24 hours post TDN compared to baseline. The stiffness increase at 24 hours was
not statistically significant.
Table 4.8 Muscle stiffness values before and after dry needling.
Infraspinatus
Pre
Post
24 hour
Erector Spinae
Pre
Post
24 hour
Gastrocnemius
Pre
Post
24 hour

MyotonPRO® (N/m)
Mean (95% CI)
291.1 (264.5, 317.7)
279.8 (251.7, 307.8)
302.6 (275.2, 330.0)

-11.4 (-26.7, 4.0)
11.5 (-1.1, 24.1)

225.9 (187.9, 263.8)
220.5 (177.01, 263.9)
237.5 (196.62, 278.4)

-5.4 (-27.6, 16.8)
11.7 (-15.8, 39.1)

329.0 (284.3, 373.6)
296.8 (263.8, 398.1)*
353.6 (309.1, 398.1)

-32.2 (-51.2, -13.2)
24.7 (-11.2, 60.5)

Mean Difference (95% CI)

*p < 0.05 significant difference

A one-way ANOVA was repeated in the subgroup of individuals that
demonstrated a localized twitch response (LTR) in the infraspinatus, erector spinae, and
gastrocnemius (Table 4.9). A total of 30 subjects from the sample of 60 experienced an
LTR broken up into the following groups: infraspinatus 8; erector spinae 7; and
gastrocnemius 15. The LTR subgroup of subjects demonstrated a decrease in mean
stiffness immediately after TDN. The erector spinae group change in stiffness was
significant, F(2,7) = 5.88, p=0.017. The gastrocnemius group change in stiffness was
significant, F(2,13) = 11.71, p<0.001. The decrease in stiffness was absent in all groups
after 24 hours with measurements returning to near baseline values.
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Table 4.9 Muscle stiffness values before and after dry needling in subjects with a
localized twitch response.
MyotonPRO® (N/m)
Infraspinatus (n=8)
Mean (95% CI)
Pre
276.6 (228.4, 324.9)
Post
256.9 (203.7, 310.1)
24 hour
284.6 (235.3, 334.0)
Erector Spinae (n=7)
Pre
223.3 (172.0, 274.6)
Post
189.3 (141.9, 236.7)*
24 hour
227.1 (161.4, 293.0)
Gastrocnemius (n=15)
Pre
353.1 (300.5, 405.8)
Post
310.9 (272.0, 349.9)*
24 hour
376.6 (324.6, 428.6)
*p < 0.05 significant difference

Mean Difference (95% CI)
-19.8 (-50.2, 10.7)
8.0 (-19.9, 35.9)

-34.0 (-67.1, -0.9)
3.9 (-43.8, 51.5)

-42.2 (-63.8, -20.6)
23.5 (-23.5, 70.4)

SUMMARY
The results of this study supported the hypothesis for both specific aim 1 and
specific aim 2. The MyotonPRO® and SWE demonstrated a positive relationship across
the chosen contraction conditions, ROI 5mm (0.35-0.71) and 10mm (0.23-0.71). The
MyotonPRO® demonstrated the ability to discriminate stiffness between different muscle
contraction intensities. Lastly, the MyotonPRO® in both the erector spinae and
gastrocnemius group measured a significant immediate decrease in stiffness when a LTR
was observed during TDN of the latent MTrP.
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CHAPTER 5: DISCUSSION

INTRODUCTION
A study was conducted using two phases to investigate the biomechanical
response of TDN to a latent myofascial trigger point (MTrP) in the infraspinatus, erector
spinae, or gastrocnemius measured using the MyotonPRO®. The first phase investigated
the reliability and concurrent validity of MyotonPRO® during three different conditions
of muscle contraction. The first phase was completed using healthy subjects performing
resting and isometric contraction at 40% and 80% of their maximum voluntary
contraction (MVIC). The second phase was conducted on a different sample of healthy
subjects with a latent MTrP. Biomechanical stiffness was measured pre and post trigger
point dry needling (TDN) in either the gastrocnemius, erector spinae, or infraspinatus.
The focus of this chapter will be on interpreting the findings of the study and relating it to
existing literature. We will discuss the specific aims and describe the impact of the results
on clinical practice. Future research will be proposed and limitations of this investigation
will be discussed. A summary of the entire project will conclude this chapter.

DISCUSSION: SPECIFIC AIM 1
The quantitative measurement of muscle stiffness in the clinic is a new approach
to objectifying one aspect of the biomechanical state of the muscle. The purpose of this
phase of the study was to investigate the concurrent validity and reliability of the
MyotonPRO® as compared to the criterion of shear wave elastography (SWE) in the
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measurement of biomechanical stiffness in the infraspinatus, erector spinae, and
gastrocnemius of healthy subjects over increasing muscle contraction.
Stiffness measurement provides enhanced understanding of the musculoskeletal
impairments at the tissue level, and baseline measures to possibly track rehabilitation
treatment effectiveness in the short and long term. The results from this study suggest
both measurement techniques are reliable for use in the clinic. Specifically, the single and
average of 3 measures demonstrated excellent reliability for MyotonPRO®. Using one
MyotonPRO® measurement or an average of 3 measures in the clinical setting will
provide equitable measurement reliability leaving the decision up to the clinician as to
which approach to use. A single SWE measurement intraclass correlation coefficient
(ICC) model 3,1 demonstrated lower reliability (ICCs 0.30-0.95). A mean of 3 SWE
measurements (ICC 3,3) improved reliability over the single measures approach in every
case (ICC 0.56-0.98). However, the reliability of a mean of 3 for the infraspinatus 80%
MVIC measurement was ICC=0.56 which is under the very minimum of acceptable at
0.70.104 Preference should be given to the mean of 3 measures, as the total time invested
to capture additional measures is small. This supports previous recommendation for an
average of three ultrasound measures given the relatively small amount of time required
to capture additional measurements.102
This study provides support for the MyotonPRO® to detect different states of
muscle contraction, which were theorized to reflect varying conditions of stiffness.
Increases in mean muscle stiffness with greater muscle contraction intensities were
hypothesized. Previous studies found muscle stiffness to be linearly related to muscle
force during isometric contraction.30,105-107 The MyotonPRO® demonstrated the ability to
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discriminate between different muscle contraction intensities. Observable increases in
stiffness occurred between resting, 40% MVIC, and 80% MVIC conditions in the three
chosen muscles. The magnitude of the mean differences was greater between resting and
contraction (40% or 80% MVIC) than between the active contractions themselves. The
certainty of this discriminative ability can be reflected in the low coefficient of variation
for the MyotonPRO® due to a smaller dispersion of measured values.
Discriminate validity was not consistently demonstrated with the SWE
measurements. Only the 5mm ROI gastrocnemius and 10mm ROI erector spinae were
statistically significant across contraction conditions. While overall mean values for
stiffness increased between resting and contraction for each muscle tested, they were not
consistently different. The SWE at 5mm ROI demonstrated greater coefficient of
variation percentages. Observable plateau of SWE stiffness between 40% and 80%
MVIC was present in the infraspinatus and erector spinae. This may indicate that muscle
stiffness changes at these levels cannot be detected with the SWE for some muscles.
Alternatively, other surrounding muscles may have been recruited with higher
contraction levels. Skeletal muscle rarely contracts in isolation from the surrounding
musculature. Rather groups of muscles share the contraction based on the load required to
complete the movement pattern.108 Load sharing during isometric contraction was
demonstrated with elbow flexion resulting in measureable SWE stiffness plateauing in
brachialis compared to biceps brachii.108 This load sharing could explain the plateau of
stiffness values with SWE. This observed plateau was not observed in the MyotonPRO
measurements and may be unique to the SWE technique. Discreet measurement of a
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section of muscle using SWE may be very different than the surface measurement of
MyotonPRO®.
Certainty of the mean value for SWE measurement may be questioned due to the
relatively high coefficient of variation. Use of SWE during dynamic conditions of muscle
contraction may result in a measurement that is less precise. Controlling for SWE
measurement location with respect to depth is unrealistic as the muscle fibers and tissue
alter position during contraction while the transducer remains static on the skin.
MyotonPRO® may be less susceptible to this as a superficial measurement.
Few recommendations exist to standardize SWE technical settings. Kot et al
suggested utilizing a mean value of elastic modulus as the ROI size does not influence
the measurement.111 This was not observed in our study as 5mm and 10mm ROI mean
values significantly differed for six out of the nine contraction conditions. The
MyotonPRO® and SWE demonstrated a positive relationship across the chosen
contraction conditions, ROI 5mm (0.35-0.71) and 10mm (0.23-0.71). This is encouraging
evidence for the clinical use of MyotonPRO® in substitution of SWE. One previous
study reported an inability to significantly correlate the SWE to a mechanical stiffness
meter in resting neck musculature.112 However the mechanical device used in this prior
study does not operate using the principle of Young’s modulus.114 The MyotonPRO®
and SWE both operate using the principle of Young’s modulus to estimate a measure of
stiffness, but a cautious recommendation is warranted because the values of Young’s
modulus may depend heavily on the methods by which it is obtained.115 The
MyotonPRO® relies on indentation of the tissue which may be localized to superficial
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structures.115 Thus the interpretation of superficial muscle stiffness may be unrelated to a
smaller and deeper measurement provided by SWE.
In summary, dynamic muscular conditions create challenges to measurement of
stiffness but could serve as a relevant biomarker for health monitoring.117,118,139
MyotonPRO® may represent a reliable and valid approach to clinical measurement
regionally across muscle contraction conditions due to the superficial technique but may
not be as specific to localized tissue at depth with SWE.

DISCUSSION: SPECIFIC AIM 2
Previous research has not fully explained the underlying therapeutic mechanism
of TDN for MTrPs. Spontaneous electrical activity has been reported in the location of
latent MTrPs.58 The hyper-excitability of the motor end plate in latent MTrPs may
contribute to localized sustained contraction of muscle fibers and subsequent muscle
cramping, pain and tenderness.140 TDN treatment has been shown to decrease pain,
increase pressure pain threshold, improve range of motion, and decrease muscle
tone.109,141-143 There is likely both mechanical and neurophysiologic effects occurring
with TDN treatment but these effects may be limited to immediate and short term
changes.144 Therefore the purpose of this study was to investigate the biomechanical
effect of TDN to a latent MTrP in the infraspinatus, erector spinae, or gastrocnemius
measured using the MyotonPRO®.
The quantification of MTrPs biomechanical stiffness and the immediate change
following TDN has been reported using a SWE.35 Maher et al reported the stiffness of a
MTrP in the upper trapezius decreased 29.5% immediately following TDN in a sample of
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seven subjects.35 In the present study, a significant immediate decrease in stiffness was
measured in both the erector spinae and the gastrocnemius when a localized twitch
response (LTR) was observed. The erector spinae stiffness decreased 15% and the
gastrocnemius stiffness decreased 11% from measured baseline. This change was
followed by a measured return to near baseline at 24 hours post needling. The Maher et al
study did not report 24 hour results. TDN in symptomatic subjects with active MTrPs
may result in different stiffness measurements over the course of 24 hours.
Decreased motor end plate activity and improved physiologic conditions may
affect the measured stiffness of the latent MTrP. Significant reduction of spontaneous
electrical activity within the MTrP region following TDN has been reported.131,132 All
groups demonstrated a trend of decreased stiffness but this was only significant in the
gastrocnemius group with the largest mean difference of -32.2 N/m. A decrease in local
muscle stiffness while at rest indicates a physiologic dampening of the latent MTrP. The
exact duration of decreased stiffness is unknown, however, it does not appear to last
greater than 24 hours. The immediate but temporary effects of TDN are similarly
reported in other manual therapy treatments such as spinal manipulation.145
The mean difference for infraspinatus, erector spinae, and gastrocnemius was also
greater in those with a LTR. The LTR was observed in 30 of the 60 subjects, and 15 of
those where in the gastrocnemius latent MTrP group. The role and clinical importance of
LTR in treatment is not clearly established in research and may not be essential to
treatment effectiveness.146,147 Eliciting a LTR is theorized to interrupt the mechanical,
chemical, and electrical contributions to the MTrP.60 However, the mechanism of action
remains to be elucidated. LTR during TDN treatment has been correlated to a decrease or
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normalization in motor end plate activity.126,131,148-150 Changes to the local MTrP’s
biochemistry have been shown to occur following LTR.74,75 The decreased spontaneous
electrical activity recorded may be a result of the biomechanical disruption of the motor
end plate.124 Pistoning the needle can cause mechanical injury to the surrounding tissue
including the neuromuscular junction.124
In conclusion, the immediate decrease in stiffness is an objective variable of the
effect of TDN, independent of the subjective nature of pain measurement. TDN of latent
MTrPs in the gastrocnemius and erector spinae caused a significant decrease in
biomechanical stiffness of the muscle in those that also presented with a LTR. Clinical
observation of LTR combined with measurement of biomechanical stiffness may be a
beneficial biomarker for successful outcome.

RECOMMENDATIONS FOR FUTURE RESEARCH
Stiffness contributes to biomechanical stability.151,152 Further, stiffness may affect
muscle performance and increase the risk of musculoskeletal injury in the lower
extremity.4 The relationship between stiffness and injury is yet to be fully explained.
Further research investigating norms of stiffness of healthy musculoskeletal tissues in
various populations and participants with musculoskeletal pathology is recommended.
Those studies will provide a basis for research investigating ways to modify stiffness for
protective and therapeutic intervention.
In this study TDN significantly decreased the stiffness of latent MTrPs within the
erector spinae and gastrocnemius group. The infraspinatus group mean decreased but was
not significant. We recommend future research investigating stiffness changes in
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individuals with symptomatic active MTrPs and monitoring duration of change during
the first 24 hours following TDN. These changes in stiffness should be compared to other
outcome tools to determine a level of decrease that is clinically meaningful. Exploring the
role of TDN in modifying stiffness could assist in appropriate patient matched
intervention and selective management of musculoskeletal pain or injury. There appears
to be a relationship between stiffness change and LTR, which should be investigated
further. Also, future studies are necessary to determine if an LTR is clinically meaningful
for outcomes in symptomatic subjects and whether the change in stiffness is related to
overall patient improvement in other outcome measures such as pain and function.

LIMITATIONS
The limitations of the study investigating specific aim 1 should be acknowledged.
Healthy participants free from pain were used to measure stiffness changes during three
contraction conditions. The results of first phase may have limited generalizability to
other people in the population specifically those with muscle dysfunction or pain. Also
the MyotonPRO® is susceptible to measurement interference from subcutaneous fat.
Recommendations to exclude subjects based on BMI does not specifically account for the
localized superficial tissue overlaying the muscle of interest. The SWE is not susceptible
to subcutaneous tissue interference which could adversely affect the correlation overall.
However, by using varying muscle contraction intensities conditions, we attempted to
represent altered states of muscle stiffness.
The chosen levels for contraction intensities provided large intervals (0%, 40%,
80% MVIC) for the assessment of discriminate validity. Other magnitudes of differences
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in muscle contraction may be clinically important and should be investigated to fully
assess discriminate validity. Another limitation of the first phase of the study, the
measurements of stiffness were taken of the gastrocnemius, infraspinatus, and erecter
spinae in the lumbar region. The reliability and discriminate validity values may be
different in other muscles in the body. The methods of the first phase of the study did not
investigate the reliability of the examiner techniques when using the measurement
devices. The location and orientation of the measurement was strictly controlled. The
controlled aspect of the measurements gives insight to a true comparison between
measurement tools but it may not carry over into day-to-day clinical measurement.
In the second phase of this study, the primary limitation is the absence of a control
or sham group. While immediate changes occurred in measured stiffness, it is unknown
whether the change in stiffness can be attributed other variables. A placebo control group
would be beneficial for future research. Another limitation is the reported reliability
issues with MTrP identification.61,62 However, the reliability is reported to improve with
experienced clinicians and using standardized diagnostic criteria.64,65 In the study, the
measures were taken in healthy subjects with latent MTrP located in the gastrocnemius,
infraspinatus, and erecter spinae in the lumbar region. Results may vary in other
musculature and it is unknown if a similar effect will occur in active MTrPs or in
symptomatic subjects. The clinical meaningfulness of an immediate change in stiffness
decrease is not known and was not addressed by this study.
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SUMMARY
Structural changes in skeletal muscle can occur with injury and chronic pain
causing abnormal function.1-3 Muscle that undergoes structural change may lead to
altered elasticity and increased risk of injury.153 Preliminary observations suggest that
muscular injuries have unique stiffness properties that can be characterized with novel
measurement techniques.8-11 Measurement of tissue stiffness affords an opportunity to
progress the understanding of muscle structural deficits such as MTrPs that may be
related to injury.12,13
MTrPs are characterized as hyperalgesiac taut fibers of skeletal muscle.19,55 The
taut fibers within the muscle create palpable bands or nodules that may cause local pain,
and refer pain elsewhere with soft tissue examination.19 MTrPs are localized areas of
increased stiffness within the muscle but the direct relationship of MTrPs and injury is
not well established and poorly understood. MTrPs are postulated to occur following
biomechanical stress of the muscle which precipitates the development of a taut band.67
Gerwin et al proposed that submaximal repetitive muscle contractions, sustained
postures, and acute maximal overload could lead to the evolvement of the MTrP.67,68
Biomechanical overload results in an energy crisis with persistent small muscle fiber
contraction around the motor endplate. The taut band is theorized to continue due to
motor end plate dysfunction following muscle fiber injury.68,71,72
Muscle stiffness is a measureable variable that affects the performance of
movement and risk of injury.154 Stiffness affects shock absorption and contraction of the
individual muscle tendon, limb, or system.153 Evidence demonstrates that muscle stiffness
can be modified though exercise.155-157 TDN interventions are also used to target MTrPs,
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which are stiff bands within muscle. The objective measurement of stiffness may serve as
a useful outcome tool to understand the role of TDN intervention in clinical practice. The
measurements of biomechanical properties may also assist future investigations into the
mechanism of action of TDN. The purpose of this study was to first investigate the
reliability and concurrent validity of the measurement of muscle stiffness using novel
technology. The second specific aim of this study was to investigate the biomechanical
effects of TDN to MTrPs using the MyotonPRO® to measure stiffness.
We conducted a two-phase study. In the first phase of the study, a sample of 30
asymptomatic subjects was recruited from all Department of Defense beneficiary
categories (active duty, retiree, dependents, etc.) between the age of 18 and 65 years of
age. We compared the stiffness measurements of the MyotonPRO and the SWE at the
infraspinatus, erector spinae, and gastrocnemius. Muscle stiffness measurements where
collected during rest, 40% and 80% MVIC.
Multiple one way repeated measures analysis of variance (ANOVA) with
Bonferroni post hoc was conducted to evaluate for differences in muscle stiffness
between the three levels of muscle contraction (rest, 40% MVIC, and 80% MVIC) for
each measurement tool (MyotonPRO® and SWE) and for each muscle (infraspinatus,
erector spinae, and gastrocnemius). The three levels of muscle contraction elicited
statistically significant changes in stiffness as measured by the MyotonPRO® (N/m) in
all three muscles. The shear elastic modulus, as measured by shear wave elastography,
was statistically different for gastrocnemius 5mm ROI across the three contraction
conditions, F(2,58) = 61.18, p < .001. There were no significant differences between
contraction conditions for the infraspinatus or the erector spinae using the 5mm ROI. The
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SWE shear elastic modulus using 10mm ROI was statistically significant for 40% and
80% MVIC, as compared to the resting condition in the erector spinae muscle F(2,58) =
18.64, p < .001. There was no significant difference between the 40% and 80% MVIC.
There were no differences between contraction conditions for the gastrocnemius and
infraspinatus using the SWE.
Intrarater reliability was calculated using a two way mixed model, intraclass
correlation coefficient single measure and a mean of 3 measures. Statistical significance
was set a priori for all analyses at p< .05. The following guideline was used to determine
the strength of the ICC: <0.25 no correlation; 0.25-0.5 fair; 0.5-0.75 moderate to good;
and >0.75 good to excellent correlation.103Intrarater reliability estimates were excellent
(ICC > 0.93) for all MyotonPRO® measures. Intrarater reliability estimates for the SWE
measures were lower when using a single measure and improved based on a mean of 3
measurements (ICC = 0.56 to 0.98) in each muscle across all contraction conditions
Pearson’s product-moment correlation was conducted to assess the relationship
between stiffness measured by the MyotonPRO® and SWE (ROI 5mm and 10mm) in
three muscles during rest, 40%MVIC, and 80% MVIC. The following guideline was used
to determine the strength of the association.138 A small correlation ranges 0.1 to 0.3. A
moderate correlation ranges between 0.3 and 0.5. A strong correlation is greater than 0.5.
The correlation between measures was strong for gastrocnemius (r=0.71).
In conclusion of the first phase, the MyotonPRO® demonstrated excellent
measurement reliability in a laboratory setting. The MyotonPRO® also demonstrated the
ability to discriminate stiffness at different levels of contraction. The MyotonPRO® is
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less expensive and more portable than the SWE. This first phase provided the necessary
criteria for the MyotonPRO® to be used in the second phase of the study.
In the second phase of this study, a sample of 60 healthy individuals between the
ages of 18 and 65, without musculoskeletal complaints, and who have palpable, latent
MTrPs were recruited. The 3 groups were formed by the location of the MTrP: shoulder
(infraspinatus), calf (gastrocnemius), or low back (erector spinae). MyotonPRO®
stiffness measurements were collected at the latent MTrP while in a resting prone
position. TDN was performed to the MTrP and any incident of a localized twitch
response was recorded. Repeat stiffness measurements were collected immediately after
TDN treatment, and again at 24 hours.
One way repeated measures ANOVA with Bonferroni post hoc was conducted to
evaluate for difference in muscle stiffness pre and post TDN (immediately and 24 hours).
The analysis was repeated in a subgroup of individuals that demonstrated a localized
twitch response during TDN. Muscle stiffness mean measurement decreased immediately
after TDN in all the groups. The gastrocnemius MTrP group significantly decreased
immediately after TDN, F(2,38) =12.62, p< 0.001. The infraspinatus and erector spinae
stiffness decrease was not statistically significant.
A total of 30 subjects from the sample of 60 experienced an LTR broken up into
the following groups: infraspinatus 8; erector spinae 7; and gastrocnemius 15. The LTR
subgroup of subjects demonstrated a decrease in mean stiffness immediately after TDN.
The erector spinae and gastrocnemius group decrease in stiffness was significant.
In conclusion, the results of this study met the goals for both specific aim 1 and
specific aim 2. The MyotonPRO® and SWE demonstrated a positive relationship across
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the chosen contraction conditions, ROI 5mm (0.35-0.71) and 10mm (0.23-0.71). The
MyotonPRO® demonstrated the ability to discriminate stiffness between different muscle
contraction intensities. Lastly, the erector spinae and gastrocnemius group demonstrated a
significant immediate decrease in stiffness when a LTR was observed during TDN of the
latent MTrP. Future studies are necessary to investigate the connection between MTrP
stiffness and clinical outcomes in subjects with musculoskeletal injury.
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Brooke Army Medical Center
INFORMED CONSENT DOCUMENT

PROTOCOL TITLE: Using Structural Health Monitoring to Improve Diagnosis and
Treatment of Chronic Pain in U.S. Service Members: Translation to a Novel Handheld
Device - Phase One
PRINCIPAL INVESTIGATOR: Shane Koppenhaver,
LTC, SP, USA
If you choose not to participate in this research study, your decision will not affect
your eligibility for care or any other benefits to which you are entitled.
DESCRIPTION/PURPOSE OF RESEARCH:
You are being asked to consider participation in this research study. The purpose of
this study is to gather data about the stiffness and function of the shoulder, back and
calf muscles using advanced measurement equipment. The novel devices are
ultrasound imaging called Shear-Wave Elastography and mechanical elastography
called MyotonPRO.
This study will enroll approximately 30 subjects at AMEDD Center and School over a
period of approximately 12 months.
During your participation in this study, you will be asked to make 1 outpatient visits
with LTC Shane Koppenhaver or with one of the associate investigators on this
study. It will not be necessary for you to return once you have completed the study
session.

You have been selected to participate in this study because you are healthy and do not
currently have pain.
PROCEDURES:
As a participant, you will undergo the following procedures:
Examination Procedures
If you agree to participate in this research study, you will first undergo a brief
examination that consists of your completing questionnaires about how your
general medical history. Then you will receive a screening physical examination to
ensure that you don’t have pain and can complete all the study procedures. The
questionnaires will take approximately 5 minutes to complete, and the physical
examination will take approximately an additional 10 minutes to complete. The
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physical examination will consist of visual inspection, range of motion, and lumbar
spine clearing maneuvers.
Ultrasound Imaging & Elastography Procedures
As a part of each physical evaluation, we will use an ultrasound imager to measure
the function of your muscle in your shoulder, back, and calf. Ultrasound is a machine
that transmits sound waves through the body and records the echoes as the sound
waves move through different structures in the body. The echoes are transformed
into images that can be viewed on a screen. Elastography is an additional capability
that allows the ultrasound machine to measure the stiffness within a specified
region of the ultrasound image. During the ultrasound measurements you will be
asked to lie on your stomach. A gel will be placed on your skin to help transmit the
sound waves. The ultrasound device will then be placed on your skin and you will
be asked to lift one arm against resistance. The MyotonPro is also used in during the
physical examination with the ultrasound. The MyotonPRO measurement provides a
brief and light tap similar to the pressure of your finger pressing into your skin. The
device measures the stiffness of your muscle directly underneath.
If you need a procedure requiring additional informed consent, a separate consent
form will be given to you before that procedure.
RISKS OR DISCOMFORTS:
The risks associated with participation in this study are minimal. There are no
known risks from the ultrasound measurements and it has been found safe to use
over the abdominal region of pregnant women. There is a risk of some muscle
soreness in your shoulder, back or calf from lifting against resistance. Based on our
experience this type of soreness is common meaning that it occurs in 1% to 25% of
participants. If present, however, the soreness should be minor and similar to
working out in the gym.
There may also be unforeseen risks associated with this study.
BENEFITS:
There is no guarantee you will receive any benefit from this study other than
knowing that the information may help future patients.
PAYMENT (COMPENSATION):
You will not receive any compensation (payment) for participating in this study.
ALTERNATIVES TO PARTICIPATION:
Choosing not to participate in this study is your alternative to volunteering for the
study.
CONFIDENTIALITY OF RECORDS OF STUDY PARTICIPATION:
Records of your participation in this study may only be disclosed in accordance with
federal law, including the Federal Privacy Act, 5 U.S.C.552a, and its implementing
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regulations. DD Form 2005, Privacy Act Statement - Military Health Records,
contains the Privacy Act Statement for the records.
By signing this consent document, you give your permission for information gained
from your participation in this study to be published in medical literature, discussed
for educational purposes, and used generally to further medical science. You will
not be personally identified; all information will be presented as anonymous data.
Your records may be reviewed by the U.S. Food & Drug Administration (FDA), other
U.S. government agencies, and the BAMC Institutional Review Board.
Complete confidentiality cannot be promised, particularly for military personnel,
because information regarding your health may be required to be reported to
appropriate medical or command authorities. Additionally, although efforts are
made to protect your study records, it is possible that your confidentiality may be
breached by unplanned loss of your records.
ENTITLEMENT TO CARE:
In the event of injury resulting from this study, the extent of medical care provided
is limited and will be within the scope authorized for Department of Defense (DoD)
health care beneficiaries.
Your entitlement to medical and dental care and/or compensation in the event of
injury is governed by federal laws and regulations, and if you have questions about
your rights as a research subject or if you believe you have received a researchrelated injury, you may contact the Brooke Army Medical Center Protocol
Coordinators, (210) 916-2598 or BAMC Judge Advocate General, (210) 916-8585.
BLOOD & TISSUE SAMPLES:
No blood or tissue samples will be taken as part of this study.
VOLUNTARY PARTICIPATION:
The decision to participate in this study is completely voluntary on your part. No
one has coerced or intimidated you into participating in this project. You are
participating because you want to. The Principal Investigator or one of his
associates has adequately answered any and all questions you have about this study,
your participation, and the procedures involved. If significant new findings develop
during the course of this study, that may relate to your decision to continue
participation, you will be informed.
You may withdraw this consent at any time and discontinue further participation in
this study without affecting your eligibility for care or any other benefits to which
you are entitled. Should you choose to withdraw, you must notify LTC Koppenhaver
or another study investigator; no other procedures need to be taken. Your condition
will continue to be treated in accordance with acceptable standards of medical
treatment.
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The investigator of this study may terminate your participation in this study at any
time if he feels this to be in your best interest.
CONTACT INFORMATION:
Principal Investigator (PI)
The Principal Investigator or a member of the AMEDD C&S Physical Therapy faculty
and will be available to answer any questions concerning procedures throughout
this study.
Principal Investigator: LTC Shane Koppenhaver, PT, PhD, OCS
Phone: (210) 221-8410 or (210)-722-3671
Your consent to participate in this study is given on a voluntary basis. All oral and
written information and discussions about this study have been in English, a
language in which you are fluent.
A signed and dated copy of this form will be given to you.
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SIGNATURE OF PARTICIPANT

________________________________________
Printed Name of Participant

________________________________________
Signature of Participant

______________
Date

If the patient has a stamp plate, please stamp here:

SIGNATURE OF CONSENTING INDIVIDUAL
(Can only be signed by an investigator or staff whose name is listed in the protocol
and approved to consent)

_______________________________________
Printed Name of Consenting Individual

________________________________________
Signature of Consenting Individual

______________
Date

SIGNATURE OF WITNESS TO THE CONSENT/ASSENT PROCESS
I certify that the above signed research participant has freely and voluntarily
provided written consent to participate in this research study.

_______________________________________
Printed Name of Witness

________________________________________
Signature of Witnessing Individual

______________
Date
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BRADLEY UNIVERSITY
Information and Consent Form
Study Title: Dry Needling of Myofascial Trigger Points: Quantification of the
Biomechanical Response Using a Myotonometer.
Introduction: You are being asked to participate in a research study. Your
participation is voluntary. Your decision to participate or not to participate will have
no effect on your academic standing, or job status. Please ask questions if there is
anything you do not understand. The purpose of this study is to learn about the
effect of dry needling on trigger point stiffness in the lower back, shoulder blade,
and calf muscle.
What is involved in the study?
Dry needling is a technique that utilizes a thin, solid needle to treat muscle
trigger points, or muscle knots. Sterile single-use disposable needles are used to
minimize risk of infection. As a participant you will receive dry needling to a trigger
point located in your calf muscle. This study requires three separate measurement
sessions over a 24 hour period. The intervention of dry needling takes place at the
first session only and will take approximately 15 minutes to complete. You will be
asked to return at 24 hours for repeat measurement of the trigger point stiffness,
which should last approximately 10 minutes each. Total time involves less than 1
hour. Dry needling does NOT occur on the second and third measurement session.
All participants will complete a brief health history questionnaire to determine
eligibility. The health history information will be collected and saved as deidentified data using subject identification number instead of your proper name. As
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a volunteer participant you will be asked to lie face down on a padded treatment
table. The primary investigator will locate any trigger points in your calf, low back
or back of your shoulder blade. The calf muscle, low back, and shoulder blade will be
exposed and palpated to locate a myofascial trigger point. If a trigger point is found
that will be the location of the dry needling measurement. The primary investigator
will wash hands, put on gloves and sterilize the skin. Stiffness of the trigger point
will be measured with a device that provides a brief and light impulse similar to the
pressure of your finger pressing into your skin. The device measures the stiffness of
your tissue directly underneath. There have been no side effects reported with this
measurement. Following baseline measurement, a solid thin needle will be inserted
through your skin into the trigger point and moved slightly up and down. The small
movement up and down can result in a small muscle fiber contraction and twitching
can be felt in the muscle. The dry needling intervention lasts less than 1 minute. Dry
needling of the trigger point occurs once and only repeated one time if the muscle
does not contract. The needle is removed and properly disposed of. Stiffness
measurements are immediately repeated following the dry needling and again 24
hours later.
How many people will take part in the study?
It is anticipated that no more than 60 persons will participate in this
research.
How long will I be in the study?
You will be in the study for approximately 1 day. The initial treatment and
measurement session lasts 15 minutes. You will be measured once again without
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treatment the next day to monitor changes in the muscle. The second and third
measurement session will last 10 minutes each.
What are the risks of participating in the study?
Dry needling may cause an increase in pain for one to two days followed by
an expected improvement in the overall pain state. The increased pain is related to
overactive shortened muscle bands that have not been released and to the soreness
caused by the “twitching” of the muscles. Any time a needle is used there is a risk of
infection. However, we are using new, disposable and sterile needles, and infections
are extremely rare. In the event of a suspected local infection you will be instructed
to follow up with your primary care physician. A needle placed into the muscle may
disrupt small blood vessels that can result in bleeding or bruising. In the event of
bleeding a small, sterile cotton ball will be applied with pressure until it stops. A
bandage will be placed over the area. If bruising occurs, application of ice will help.
You may also experience any of the following during treatment: A feeling of
relaxation, an increase in energy level, dizziness, nausea, sweating, or irritation at
the site of needle insertion. Fortunately, all these complications are readily
reversible and temporary. Pregnancy may be a reason to not participate or to stop
participation in this study. If you are or become pregnant, please notify the primary
investigator.

What are the benefits of participating in the study?
You will not benefit from being in this research study. We hope to gather
information that may help people in the future.
What other options are there?
97

This type of treatment may be received outside of this Study.
What about Confidentiality?
All reasonable efforts will be made to keep your personal information
confidential. We cannot guarantee absolute confidentiality. Your personal
information may be disclosed if required by law. Raw data will be stored in a locked
file, in the PI’s locked office of a building with restricted access. Research data will
be destroyed when appropriate. Personal identification will not be used in
electronic database.
Organizations or individuals that may inspect and/or copy your research
records for quality assurance and data analysis include groups such as: The
Committee on the Use of Human Subjects in Research (CUHSR).
What are the costs?
There are no costs for participation in this study. In the case of injury or
illness resulting from this study, emergency medical treatment is available but will
be provided at the usual charge at your own expense. No funds have been set aside
to compensate you in the event of injury. You will receive no payment for taking
part in this study.

What are my rights?
Taking part in this study is voluntary. You may choose not to take part or
may leave the study at any time.

Who should I call with questions or problems study?
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Questions about this study may be directed to the researcher or the research
advisor in charge of this study: Professor Joseph Kelly at (309) 677-2545 during
normal business hours.
If you have general questions about being a research participant, you may
contact the CUHSR office at (677-3877) during normal business hours. The
Chairperson of this committee will discuss the matter with you.
Documentation of informed consent

You are voluntarily making a decision to participate in this study. Your
signature means that you have read and understood the information presented and
have decided to participate. Your signature also means that the information on this
consent form has been fully explained to you and all your questions have been
answered to your satisfaction. If you think of any additional questions during the
study, you should contact the researcher(s).

I agree to participate in this study

Date

______________________________________________________ ____________
Signature of Participant or legally authorized representative
________________________________________________________________________
________________________________________________________________________
Printed Name
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SUBJECT RECRUITMENT FLYER
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Amazing Technology

FREE Muscle
Examination

Volunteers needed for research examining the function of the muscles of the shoulder,
back, and calf using new Elastography technology.
To qualify for our research, you must:
• Be between 18-65 years old
• Painfree in either the shoulder, back, or calf
• No surgery in the last 6 months

To learn more about our study, please contact:
Joseph Kelly (309) 677 – 2545
muscle.research.study@gmail.com
Center for Physical Therapy Research
Graduate School at the Academy of Health Sciences
Army Medical Department Center and School (AMEDDC&S)

PI information for Back of flyer:

FREE Muscle Exam Study
Joseph Kelly
(309) 677 – 2545

muscle.research.study@gmail.com

FREE Muscle Exam Study
Joseph Kelly
(309) 677 – 2545

muscle.research.study@gmail.com

FREE Muscle Exam Study
Joseph Kelly
(309) 677 – 2545

muscle.research.study@gmail.com

FREE Muscle Exam Study
Joseph Kelly
(309) 677 – 2545

muscle.research.study@gmail.com

FREE Muscle Exam Study
Joseph Kelly
(309) 677 – 2545

muscle.research.study@gmail.com

FREE Muscle Exam Study
Joseph Kelly
(309) 677 – 2545

muscle.research.study@gmail.com

FREE Muscle Exam Study
Joseph Kelly
(309) 677 – 2545

muscle.research.study@gmail.com

FREE Muscle Exam Study
Joseph Kelly
(309) 677 – 2545

muscle.research.study@gmail.com
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Study Principle Investigator:
LTC Shane Koppenhaver PT, PhD
Director of Research & Assistant Professor US Army Baylor University Doctoral
Physical Therapy Program
3599 Scott Rd. Suite 1301
Fort Sam Houston, TX 78234
Cell: (210) 722-3671
shanekoppenhaver@mac.com
Joseph Kelly PT, OCS
PhD student
Nova Southeastern University
(309) 677 – 2545
muscle.research.study@gmail.com

Advertisement used in email/newsletters will be one of two forms, each of which
includes a link that will take potential volunteers to an online version of above flyer.
•

Volunteers are needed to participate in a study researching imaging of low back
muscles. To qualify, volunteers must be between 18 and 65 years of age, and not have
current low back pain or a history of spinal surgery.
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